@NP	Peripheral Olfactory Ensheathing Cells	1
@NP	Scar and Cavity Formation	47
@NP	Regeneration	85
@NP	Spinal Cord Injury LEANNE M.	104
@NP	RAMER ,1,2 EDMUND AU ,1 MIRANDA W.	134
@NP	RAMER ,1,2 EDMUND	134
@NP	AU ,1	151
@NP	MIRANDA W.	156
@NP	RICHTER ,1 JIE LIU ,1,2 WOLFRAM TETZLAFF ,1,2 AND A.	167
@NP	RICHTER ,1 JIE LIU	167
@NP	,1,2 WOLFRAM TETZLAFF ,1,2 AND A.	184
@NP	,1,2 WOLFRAM TETZLAFF ,1,2	184
@NP	A.	214
@NP	JANE ROSKAMS1	217
@NP	1Department	232
@NP	Zoology	247
@NP	University	256
@NP	British Columbia , Vancouver , British Columbia V6T 1Z4	270
@NP	Canada 2International Collaboration on Repair Discoveries	325
@NP	Canada 2International Collaboration	325
@NP	Repair Discoveries	364
@NP	University	384
@NP	British Columbia , Vancouver , British Columbia V6T 1Z4	398
@NP	Canada ABSTRACT Bridging of a lesion site	453
@NP	Canada ABSTRACT Bridging	453
@NP	a lesion site	482
@NP	local damage	511
@NP	an environment permissive for regeneration	534
@NP	an environment permissive	534
@NP	regeneration	564
@NP	both primary components	581
@NP	a successful strategy to repair spinal cord injury -LRB- SCI -RRB-	608
@NP	spinal cord injury -LRB- SCI -RRB-	640
@NP	spinal cord injury	640
@NP	SCI	660
@NP	Olfactory ensheathing cells -LRB- OECs -RRB-	666
@NP	Olfactory ensheathing cells	666
@NP	OECs	695
@NP	prime candidates for autologous transplantation to bridge this gap	705
@NP	prime candidates	705
@NP	autologous transplantation	726
@NP	this gap	763
@NP	little	777
@NP	their mechanism of action	809
@NP	their mechanism	809
@NP	action	828
@NP	addition	839
@NP	OECs from the accessible lamina propria -LRB- LP -RRB- of the olfactory mucosa	849
@NP	OECs	849
@NP	the accessible lamina propria -LRB- LP -RRB-	859
@NP	the accessible lamina propria	859
@NP	LP	890
@NP	the olfactory mucosa	897
@NP	a more viable source	922
@NP	humans	946
@NP	their ability to promote regeneration in established SCI models	983
@NP	regeneration	1008
@NP	established SCI models	1024
@NP	mouse LP-OECs	1054
@NP	green fluorescent protein	1079
@NP	GFP	1106
@NP	directly into both rat and mouse dorsolateral spinal cord lesion sites	1124
@NP	both rat and mouse dorsolateral spinal cord lesion	1138
@NP	rat	1143
@NP	mouse dorsolateral spinal cord lesion	1151
@NP	limited migration	1207
@NP	host astrocytes	1243
@NP	a new transitional zone	1270
@NP	the lesion border	1297
@NP	LP-OECs	1316
@NP	extensive migration of host Schwann cells	1337
@NP	extensive migration	1337
@NP	host Schwann cells	1360
@NP	the central nervous system repair zone	1384
@NP	angiogenesis	1437
@NP	a biological scaffold for repair	1461
@NP	a biological scaffold	1461
@NP	repair	1487
@NP	This novel environment	1495
@NP	transplanted and host glia within the spinal cord	1529
@NP	transplanted	1529
@NP	host glia within the spinal cord	1546
@NP	host glia	1546
@NP	the spinal cord	1563
@NP	cavity and scar formation	1588
@NP	multiple sensory and motor axons	1650
@NP	the lesion site	1700
@NP	Sixty days	1717
@NP	rat SCI	1734
@NP	serotonin - and tyrosine hydroxylase-positive axons	1743
@NP	serotonin	1743
@NP	tyrosine hydroxylase-positive axons	1758
@NP	the lesion	1810
@NP	the distal cord	1826
@NP	axotomized rubrospinal axons	1852
@NP	a xenotransplant paradigm	1904
@NP	LP-OECs work	1931
@NP	host glial cells	1965
@NP	an environment to ameliorate local damage	1992
@NP	local damage	2021
@NP	a regenerative response in multiple axonal populations	2061
@NP	a regenerative response	2061
@NP	multiple axonal populations	2088
@NP	significant evidence	2126
@NP	some functional regeneration	2161
@NP	rodent models of spinal cord injury -LRB- SCI -RRB-	2193
@NP	rodent models	2193
@NP	spinal cord injury -LRB- SCI -RRB-	2210
@NP	spinal cord injury	2210
@NP	SCI	2230
@NP	human SCI	2236
@NP	permanent neurologic deficits	2263
@NP	the variety	2321
@NP	therapies	2336
@NP	successful animal experimentation	2359
@NP	Amar and Levy , 1999 ; Edgerton and Roy , 2002 ; Fawcett , 2002	2394
@NP	Amar and Levy	2394
@NP	Amar	2394
@NP	Levy	2403
@NP	1999 ; Edgerton and Roy	2409
@NP	1999	2409
@NP	Edgerton and Roy	2415
@NP	2002 ; Fawcett , 2002	2433
@NP	2002	2433
@NP	Fawcett , 2002	2439
@NP	Fawcett	2439
@NP	2002	2448
@NP	Axons confined within the central nervous system -LRB- CNS -RRB-	2455
@NP	Axons	2455
@NP	the central nervous system	2477
@NP	CNS	2505
@NP	appropriate central targets -LRB- Ramon y Cajal , 1928 -RRB-	2558
@NP	appropriate central targets	2558
@NP	Ramon y Cajal , 1928	2587
@NP	Ramon y Cajal	2587
@NP	1928	2602
@NP	contrast	2612
@NP	peripheral nervous system -LRB- PNS -RRB- injury in adult rodents and humans	2622
@NP	peripheral nervous system -LRB- PNS -RRB- injury	2622
@NP	PNS	2649
@NP	adult rodents and humans	2664
@NP	successful axonal regeneration	2710
@NP	the adult mammalian olfactory system	2745
@NP	successful re-targeting	2792
@NP	axons in both the PNS and CNS portions of the primary olfactory neuraxis	2819
@NP	axons	2819
@NP	both the PNS and CNS portions	2828
@NP	the PNS	2833
@NP	CNS portions	2845
@NP	the primary olfactory neuraxis	2861
@NP	Adult olfactory receptor neurons -LRB- ORNs -RRB-	2905
@NP	Adult olfactory receptor neurons	2905
@NP	ORNs	2939
@NP	turnover -- apoptosis-induced replacement -- from an endogenous progenitor pool	2966
@NP	turnover -- apoptosis-induced replacement --	2966
@NP	turnover	2966
@NP	apoptosis-induced replacement	2975
@NP	an endogenous progenitor pool	3010
@NP	their axons	3045
@NP	a PNS-CNS boundary	3066
@NP	the olfactory bulb	3123
@NP	birth	3148
@NP	adulthood -LRB- Graziadei et al. , 1978 ; Schwob , 2002 -RRB-	3165
@NP	adulthood	3165
@NP	Graziadei	3176
@NP	et al. , 1978 ; Schwob , 2002	3186
@NP	et al.	3186
@NP	1978 ; Schwob	3194
@NP	1978	3194
@NP	Schwob	3200
@NP	2002	3208
@NP	Successful axonal growth and regeneration in the adult olfactory system	3215
@NP	Successful axonal growth	3215
@NP	regeneration in the adult olfactory system	3244
@NP	regeneration	3244
@NP	the adult olfactory system	3260
@NP	large part	3305
@NP	a unique population	3320
@NP	glial cells -- olfactory ensheathing cells -LRB- OECs -RRB-	3343
@NP	glial cells	3343
@NP	olfactory ensheathing cells	3355
@NP	OECs	3384
@NP	OECs	3391
@NP	ORN axons	3406
@NP	their exit point	3421
@NP	the basal lamina	3441
@NP	the olfactory mucosa -LRB- lamina propria OECs ; LP-OECs -RRB-	3461
@NP	the olfactory mucosa	3461
@NP	lamina propria OECs ; LP-OECs	3483
@NP	lamina propria OECs	3483
@NP	LP-OECs	3504
@NP	the cribriform plate	3522
@NP	the nerve fiber layer of the olfactory bulb -LRB- Doucette , 1991 -RRB-	3553
@NP	the nerve fiber layer	3553
@NP	the olfactory bulb -LRB- Doucette , 1991 -RRB-	3578
@NP	the olfactory bulb	3578
@NP	Doucette , 1991	3598
@NP	Doucette	3598
@NP	1991	3608
@NP	OECs	3615
@NP	they	3640
@NP	antigenic and morphologic characteristics	3653
@NP	astrocytes , Schwann cells , and oligodendrocytes	3698
@NP	astrocytes	3698
@NP	Schwann cells	3710
@NP	oligodendrocytes	3729
@NP	an array	3759
@NP	trophic factors	3771
@NP	transcription factors	3788
@NP	extracellular matrix molecules more typical	3815
@NP	extracellular matrix molecules	3815
@NP	Ramon-Cueto	3890
@NP	Avila , 1998	3906
@NP	Avila	3906
@NP	1998	3913
@NP	Gudino-Cabrera and Nieto-Sampedro , 1999	3919
@NP	Gudino-Cabrera and Nieto-Sampedro	3919
@NP	1999	3954
@NP	Chuah and West , 2002	3960
@NP	Chuah and West	3960
@NP	2002	3976
@NP	Au and Roskams , 2003	3982
@NP	Au and Roskams	3982
@NP	2003	3998
@NP	they	4013
@NP	axonal regeneration	4026
@NP	the CNS portion of the olfactory system	4063
@NP	the CNS portion	4063
@NP	the olfactory system	4082
@NP	olfactory bulb-derived ensheathing cells -LRB- OB-OECs -RRB-	4104
@NP	olfactory bulb-derived ensheathing cells	4104
@NP	OB-OECs	4146
@NP	significant promise	4204
@NP	regeneration	4237
@NP	spinal cord lesion	4256
@NP	Bartolomei and Greer , 2000 ; Bunge , 2002	4288
@NP	Bartolomei and Greer	4288
@NP	2000 ; Bunge , 2002	4310
@NP	2000	4310
@NP	Bunge , 2002	4316
@NP	Bunge	4316
@NP	2002	4323
@NP	OBOECs	4330
@NP	regeneration of sensory and descending axons to varying degrees	4356
@NP	regeneration	4356
@NP	sensory and descending axons to varying degrees	4372
@NP	sensory	4372
@NP	descending axons to varying degrees	4384
@NP	descending axons	4384
@NP	varying degrees	4404
@NP	the site	4441
@NP	thoracic spinal transection	4453
@NP	fine electrolytic lesion	4482
@NP	hemisection	4508
@NP	moderate contusion in adult rat	4524
@NP	moderate contusion	4524
@NP	adult rat	4546
@NP	Li	4557
@NP	et al. , 1997	4560
@NP	et al.	4560
@NP	1997	4568
@NP	Ramon-Cueto et al. , 1998	4574
@NP	Ramon-Cueto	4574
@NP	et al. , 1998	4586
@NP	et al.	4586
@NP	1998	4594
@NP	Nash et al. , 2002	4600
@NP	Nash	4600
@NP	et al. , 2002	4605
@NP	et al.	4605
@NP	2002	4613
@NP	Takami et al. , 2002	4619
@NP	Takami	4619
@NP	et al. , 2002	4626
@NP	et al.	4626
@NP	2002	4634
@NP	the OEC transplantation field	4656
@NP	widely different protocols for preparing OECs	4710
@NP	widely different protocols	4710
@NP	OECs	4751
@NP	minimal accounting	4757
@NP	cellular purity or heterogeneity	4784
@NP	cellular purity	4784
@NP	heterogeneity	4803
@NP	time	4833
@NP	culture or frequency of passage	4841
@NP	culture or frequency	4841
@NP	passage	4865
@NP	a variety of delivery techniques	4878
@NP	a variety	4878
@NP	delivery techniques	4891
@NP	Franklin , 2002	4924
@NP	Franklin	4924
@NP	2002	4934
@NP	It	4941
@NP	the integration	5000
@NP	fate	5017
@NP	migration patterns	5027
@NP	transplanted OECs due to problems with marking the cells stably enough	5049
@NP	transplanted OECs	5049
@NP	problems	5074
@NP	the cells	5096
@NP	them	5130
@NP	the complex environment of a spinal cord	5138
@NP	the complex environment	5138
@NP	a spinal cord	5165
@NP	This tracking	5180
@NP	an essential component	5207
@NP	OEC mechanisms of action	5247
@NP	OEC mechanisms	5247
@NP	action	5265
@NP	their use	5284
@NP	a transplantation approach	5297
@NP	OECs	5325
@NP	a defining molecular marker	5335
@NP	share multiple antigenic and morphologic characteristics	5367
@NP	share	5367
@NP	multiple antigenic and morphologic characteristics	5373
@NP	endogenous glia	5429
@NP	Schwann cells -LRB- Barnett et al. , 1993 -RRB-	5464
@NP	Schwann cells	5464
@NP	Barnett	5479
@NP	et al. , 1993	5487
@NP	et al.	5487
@NP	1993	5495
@NP	Dye-loading of cells before transplantation	5502
@NP	Dye-loading	5502
@NP	cells before transplantation	5517
@NP	cells	5517
@NP	transplantation	5530
@NP	several cases	5563
@NP	vital dyes	5582
@NP	leak	5604
@NP	phagocytic cells	5637
@NP	interpretation	5711
@NP	these data -LRB- Iwashita et al. , 2000 ; Ruitenberg et al. , 2002 -RRB-	5729
@NP	these data	5729
@NP	Iwashita	5741
@NP	et al. , 2000 ; Ruitenberg et al. , 2002	5750
@NP	et al.	5750
@NP	2000 ; Ruitenberg et al.	5758
@NP	2000	5758
@NP	Ruitenberg et al.	5764
@NP	Ruitenberg	5764
@NP	et al.	5775
@NP	2002	5783
@NP	OB-OECs	5804
@NP	transplantation paradigms	5841
@NP	their use	5872
@NP	acute SCI models	5913
@NP	Their peripheral counterparts , LP-OECs ,	5931
@NP	Their peripheral counterparts	5931
@NP	LP-OECs	5962
@NP	a more accessible source for potential autotransplantation in human SCI	5981
@NP	a more accessible source	5981
@NP	potential autotransplantation in human SCI	6010
@NP	potential autotransplantation	6010
@NP	human SCI	6043
@NP	untested in animal models of SCI	6064
@NP	untested	6064
@NP	animal models of SCI	6076
@NP	animal models	6076
@NP	SCI	6093
@NP	Grafted strips	6098
@NP	dissociated suspensions	6116
@NP	olfactory mucosa	6143
@NP	a highly heterogeneous mixture of different cells	6172
@NP	a highly heterogeneous mixture	6172
@NP	different cells	6206
@NP	regeneration of brainstem and sensory axons -LRB- Lu et al. , 20012002 -RRB-	6247
@NP	regeneration	6247
@NP	brainstem and sensory axons -LRB- Lu et al. , 20012002 -RRB-	6263
@NP	brainstem and sensory axons	6263
@NP	Lu	6292
@NP	et al. , 20012002	6295
@NP	et al.	6295
@NP	20012002	6303
@NP	these data	6318
@NP	the initiation	6349
@NP	human trials	6367
@NP	autotransplantation of uncharacterized LPOECs in patients with chronic SCI	6386
@NP	autotransplantation	6386
@NP	uncharacterized LPOECs in patients with chronic SCI	6409
@NP	uncharacterized LPOECs	6409
@NP	patients with chronic SCI	6435
@NP	patients	6435
@NP	chronic SCI	6449
@NP	ausbioinfo.com/news/articles/2002-07-12_108.php	6474
@NP	we	6530
@NP	LP-OECs	6568
@NP	endogenous enhanced green fluorescent protein	6587
@NP	GFP	6634
@NP	acute spinal cord injury in immunesuppressed rats and mice	6644
@NP	acute spinal cord injury	6644
@NP	immunesuppressed rats and mice	6672
@NP	GFP fluorescence	6717
@NP	species-specific antibodies	6739
@NP	we	6768
@NP	transplanted LP-OECs	6795
@NP	the regeneration environment of the spinal cord in both xeno	6824
@NP	the regeneration environment	6824
@NP	the spinal cord in both	6856
@NP	the spinal cord	6856
@NP	allotransplant SCI models	6890
@NP	we	6923
@NP	LP-OECs	6938
@NP	a novel interaction between host glial cells	6965
@NP	a novel interaction	6965
@NP	host glial cells	6993
@NP	the spinal cord lesion environment	7021
@NP	a new transitional environment	7067
@NP	multiple axonal tracts	7104
@NP	a regeneration response	7148
@NP	MATERIALS AND METHODS	7174
@NP	OECs	7211
@NP	GFP mice	7221
@NP	OECs	7230
@NP	the olfactory mucosa	7268
@NP	homozygous transgenic mice	7292
@NP	eGFP	7330
@NP	-LRB- GFP-U-NAGY ; generated	7335
@NP	GFP-U-NAGY	7336
@NP	Andreas Nagy , U.	7361
@NP	Toronto ; kind gift of Frank Jirik , U.	7378
@NP	Toronto	7378
@NP	kind gift of Frank Jirik , U.	7387
@NP	kind gift	7387
@NP	Frank Jirik , U.	7400
@NP	Frank Jirik	7400
@NP	U.	7413
@NP	Calgary -RRB-	7416
@NP	a combination	7436
@NP	betta-actin promoter and CMV-enhancer -LRB- Au and Roskams , 2003 -RRB-	7453
@NP	betta-actin promoter and CMV-enhancer	7453
@NP	Au and Roskams	7492
@NP	2003	7508
@NP	Each culture	7515
@NP	10 to 12	7546
@NP	postnatal day -LRB- P -RRB- P5 -- P7 mouse olfactory turbinates	7565
@NP	postnatal day -LRB- P -RRB- P5	7565
@NP	postnatal day	7565
@NP	P	7580
@NP	P5	7583
@NP	P7 mouse olfactory turbinates	7586
@NP	P7 mouse	7586
@NP	olfactory turbinates	7595
@NP	1.2 mg/ml collagenase D	7631
@NP	3 U/ml dispase	7656
@NP	I	7671
@NP	30 µg/ml hyaluronidase , and 100 U/ml DNAse I for 1 hour at 37 °C ,	7674
@NP	30 µg/ml hyaluronidase	7674
@NP	100 U/ml DNAse I for 1 hour at 37 °C	7702
@NP	100 U/ml DNAse I	7702
@NP	1 hour at 37 °C	7723
@NP	1 hour	7723
@NP	37 °C	7733
@NP	centrifugation and plating	7746
@NP	all enzymes from Roche Diagnostics	7774
@NP	all enzymes	7774
@NP	Roche Diagnostics	7791
@NP	Laval , Quebec , Canada	7810
@NP	Laval	7810
@NP	Quebec , Canada	7817
@NP	Cells	7834
@NP	4 days	7868
@NP	-LRB- DIV -RRB- in MEM-d-valine with 10 % heat-inactivated fetal bovine serum	7884
@NP	-LRB- DIV -RRB-	7884
@NP	MEM-d-valine with 10 % heat-inactivated fetal bovine serum	7893
@NP	MEM-d-valine	7893
@NP	10 % heat-inactivated fetal bovine serum	7911
@NP	1 % -LRB- 100 U/ml -RRB- penicillin/streptomycin	7955
@NP	1 %	7955
@NP	100 U/ml	7959
@NP	penicillin/streptomycin	7969
@NP	pen/strep ; Life Technologies	7994
@NP	pen/strep	7994
@NP	Life Technologies	8005
@NP	Rockville , MD	8024
@NP	Rockville	8024
@NP	MD	8035
@NP	anti-Thy 1.1	8047
@NP	mediated complement lysis	8061
@NP	contaminating fibroblasts	8121
@NP	Au and Roskams	8148
@NP	2003	8164
@NP	Thy1 .1 antibody-mediated complement lysis	8171
@NP	Thy1	8171
@NP	.1 antibody-mediated complement lysis	8175
@NP	8 DIV	8229
@NP	OECs	8248
@NP	confluency -LRB- 2 -- 4 further DIV -RRB-	8261
@NP	confluency	8261
@NP	2 -- 4 further DIV	8273
@NP	2	8273
@NP	4 further DIV	8275
@NP	transplantation	8297
@NP	All cells for transplantation	8314
@NP	All cells	8314
@NP	transplantation	8328
@NP	48 hours	8356
@NP	surgery at 5,800 cells	8372
@NP	surgery	8372
@NP	5,800 cells	8383
@NP	cm2 in individual T25 or T75 flasks	8396
@NP	cm2	8396
@NP	individual T25 or T75 flasks	8403
@NP	-LRB- Sigma , St.	8432
@NP	Louis	8444
@NP	MO	8451
@NP	one flask of cells	8465
@NP	one flask	8465
@NP	cells	8478
@NP	transplantation	8512
@NP	each animal	8533
@NP	The total time from dissection to transplantation	8546
@NP	The total time	8546
@NP	dissection to transplantation	8566
@NP	dissection	8566
@NP	transplantation	8580
@NP	11	8608
@NP	14 DIV	8614
@NP	initial experiments by using freshly prepared LPOECs	8628
@NP	initial experiments	8628
@NP	freshly prepared LPOECs	8657
@NP	maintenance of phenotype	8691
@NP	maintenance	8691
@NP	phenotype	8706
@NP	cryopreservation of cells	8722
@NP	cryopreservation	8722
@NP	cells	8742
@NP	some experiments	8749
@NP	3 of 28-day rats , all 60-day rats , and all 28-day mice	8767
@NP	3	8767
@NP	28-day rats , all 60-day rats , and all 28-day mice	8772
@NP	28-day rats	8772
@NP	all 60-day rats	8785
@NP	all 28-day mice	8806
@NP	OECs	8828
@NP	9 DIV	8863
@NP	1	8876
@NP	day	8878
@NP	second Thy1 .1 antibody-mediated complement lysis	8888
@NP	second Thy1	8888
@NP	.1 antibody-mediated complement lysis	8899
@NP	Immunocytochemistry	8939
@NP	the second round of complement lysis	8965
@NP	the second round	8965
@NP	complement lysis	8985
@NP	a small aliquot of each culture	9003
@NP	a small aliquot	9003
@NP	each culture	9022
@NP	immunocytochemistry	9052
@NP	the purity of OECs used for grafting	9085
@NP	the purity	9085
@NP	OECs used for grafting	9099
@NP	OECs	9099
@NP	Primary antibodies used to test culture purity	9123
@NP	Primary antibodies	9123
@NP	culture purity	9155
@NP	anti- S100betta -LRB- 1:500 , Sigma -RRB-	9175
@NP	anti- S100betta	9175
@NP	1:500	9192
@NP	Sigma	9199
@NP	low-affinity nerve growth factor receptor	9207
@NP	p75 ; 1:500	9250
@NP	p75	9250
@NP	1:500	9255
@NP	Chemicon , Temecula , CA	9262
@NP	Chemicon	9262
@NP	Temecula , CA	9272
@NP	glial fibrillary acidic protein	9291
@NP	GFAP ; 1:1000	9324
@NP	GFAP	9324
@NP	1:1000	9330
@NP	DakoCytomation , Denmark	9338
@NP	DakoCytomation	9338
@NP	Denmark	9354
@NP	4 °C	9376
@NP	Cells	9381
@NP	secondary antibodies	9407
@NP	1:200	9429
@NP	Jackson ImmunoResearch	9436
@NP	Mississauga , ON	9460
@NP	goat	9487
@NP	Alexa 594	9510
@NP	1 hour at room temperature	9524
@NP	1 hour	9524
@NP	room temperature	9534
@NP	Hoechst	9562
@NP	33258	9570
@NP	1 µg/ml	9577
@NP	Sigma	9586
@NP	1 minute	9597
@NP	cover-slipped in glycerol mounting medium -LRB- Sigma -RRB-	9611
@NP	cover-slipped	9611
@NP	glycerol mounting medium -LRB- Sigma -RRB-	9628
@NP	glycerol mounting medium	9628
@NP	Sigma	9654
@NP	Crush injury	9662
@NP	the dorsolateral funiculus Male	9678
@NP	Sprague-Dawley rats	9710
@NP	n = 33 , 150 -- 200 g , Charles River Breeding Laboratories	9731
@NP	n	9731
@NP	= 33 , 150 -- 200 g , Charles River Breeding Laboratories	9733
@NP	= 33 , 150	9733
@NP	= 33	9733
@NP	150	9739
@NP	200 g , Charles River Breeding Laboratories	9743
@NP	200 g	9743
@NP	Charles River Breeding Laboratories	9750
@NP	male C57Bl/6 mice -LRB- n 12 , 25 -- 30 g , Charles River -RRB-	9791
@NP	male C57Bl/6 mice	9791
@NP	n 12 , 25 -- 30 g , Charles River	9810
@NP	n 12	9810
@NP	25 -- 30 g	9818
@NP	25	9818
@NP	30 g	9821
@NP	Charles River	9827
@NP	cyclosporin A	9869
@NP	Novartis Pharmaceuticals , Mississauga , ON ; 10 mg/kg per day , i.p.	9884
@NP	Novartis Pharmaceuticals , Mississauga , ON ; 10 mg/kg per day	9884
@NP	Novartis Pharmaceuticals , Mississauga , ON	9884
@NP	Novartis Pharmaceuticals	9884
@NP	Mississauga , ON	9910
@NP	10 mg/kg per day	9927
@NP	10 mg/kg	9927
@NP	day	9940
@NP	2 days	9962
@NP	injury and OEC transplantation	9976
@NP	survival	10038
@NP	All animal procedures	10048
@NP	accordance	10088
@NP	the guidelines of the Canadian Council for Animal Care	10104
@NP	the guidelines	10104
@NP	the Canadian Council for Animal Care	10122
@NP	the Canadian Council	10122
@NP	Animal Care	10147
@NP	our institution 's animal care committee	10175
@NP	our institution 's	10175
@NP	Animals	10216
@NP	ketamine -LRB- 70 mg/kg , i.p. -RRB- and xylazine -LRB- 10 mg/kg , i.p. -RRB-	10247
@NP	ketamine	10247
@NP	70 mg/kg , i.p.	10257
@NP	70 mg/kg	10257
@NP	xylazine	10277
@NP	10 mg/kg , i.p.	10287
@NP	10 mg/kg	10287
@NP	A hemilaminectomy	10304
@NP	the left half of the fourth cervical spinal cord segment -LRB- C4 -RRB-	10346
@NP	the left half	10346
@NP	the fourth cervical spinal cord segment -LRB- C4 -RRB-	10363
@NP	the fourth cervical spinal cord segment	10363
@NP	C4	10404
@NP	the dura	10413
@NP	microscissors	10435
@NP	Fine surgical forceps	10450
@NP	a depth of 1 mm	10489
@NP	a depth	10489
@NP	1 mm	10500
@NP	one prong at the border of the grey matter	10511
@NP	one prong	10511
@NP	the border of the grey matter	10524
@NP	the border	10524
@NP	the grey matter	10538
@NP	one prong outside the dorsolateral funiculus	10558
@NP	one prong	10558
@NP	the dorsolateral funiculus	10576
@NP	the forceps	10604
@NP	18	10641
@NP	20 seconds	10644
@NP	the dorsolateral funiculus , including the rubrospinal tract	10664
@NP	the dorsolateral funiculus	10664
@NP	the rubrospinal tract	10702
@NP	completion of the injury	10730
@NP	completion	10730
@NP	the injury	10744
@NP	animals	10756
@NP	control	10803
@NP	an investigator other than the surgeon	10814
@NP	an investigator	10814
@NP	the surgeon	10841
@NP	OEC transplantation	10854
@NP	transplantation	10893
@NP	OECs	10910
@NP	0.25 % trypsin and 1 % ethylenediaminetetraacetic acid	10933
@NP	0.25 % trypsin	10933
@NP	1 % ethylenediaminetetraacetic acid	10951
@NP	sterile phosphate	10997
@NP	saline -LRB- PBS -RRB-	11024
@NP	saline	11024
@NP	PBS	11032
@NP	Dulbecco 's	11057
@NP	Eagles medium -LRB- DMEM -RRB-	11077
@NP	Eagles	11077
@NP	DMEM	11092
@NP	50,000	11101
@NP	100,000 OECs/µl	11108
@NP	the crush injury	11140
@NP	75,000 -- 150,000 OECs	11158
@NP	75,000	11158
@NP	150,000 OECs	11165
@NP	1.5 µl	11179
@NP	cell slurry for rats , 1 µl of cell slurry for mice ,	11189
@NP	cell slurry	11189
@NP	rats , 1 µl of cell slurry for mice ,	11205
@NP	rats	11205
@NP	1 µl of cell slurry for mice	11211
@NP	1 µl	11211
@NP	cell slurry for mice	11219
@NP	cell slurry	11219
@NP	mice	11235
@NP	three injection sites	11254
@NP	the lesion site	11317
@NP	a pulled glass pipette -LRB- tip diameter = 20 µm -RRB-	11342
@NP	a pulled glass pipette	11342
@NP	tip diameter = 20 µm	11366
@NP	tip diameter =	11366
@NP	tip	11366
@NP	20 µm	11381
@NP	a Hamilton syringe	11397
@NP	The cell slurry	11417
@NP	a rate of 100 nl/min	11451
@NP	a rate	11451
@NP	100 nl/min	11461
@NP	the pipette	11477
@NP	place for 5 minutes	11501
@NP	place	11501
@NP	5 minutes	11511
@NP	each injection	11527
@NP	Control animals	11543
@NP	identical volumes of DMEM	11568
@NP	identical volumes	11568
@NP	DMEM	11589
@NP	the same rate and sites	11606
@NP	the same rate	11606
@NP	sites	11624
@NP	the final injection	11637
@NP	the pipette	11658
@NP	the muscle and skin	11695
@NP	interrupted sutures	11732
@NP	Survival times	11753
@NP	48 hours -LRB- n = 6 -RRB-	11773
@NP	n	11783
@NP	6	11787
@NP	7 days -LRB- n = 6 -RRB-	11791
@NP	n	11799
@NP	6	11803
@NP	28 days -LRB- n = 15 -RRB-	11807
@NP	n	11816
@NP	15	11820
@NP	60 days -LRB- n = 6 -RRB- for rats	11829
@NP	60 days -LRB- n = 6 -RRB-	11829
@NP	n	11838
@NP	6	11842
@NP	rats	11849
@NP	28 days -LRB- n = 12 -RRB- for mice	11858
@NP	28 days -LRB- n = 12 -RRB-	11858
@NP	n	11867
@NP	12	11871
@NP	mice	11879
@NP	Anterograde labeling	11885
@NP	rubrospinal axons One week before the end of the survival period	11909
@NP	rubrospinal axons	11909
@NP	One week	11927
@NP	the end of the survival period	11943
@NP	the end	11943
@NP	the survival period	11954
@NP	animals	11975
@NP	a Kopf stereotaxic frame	12012
@NP	dextran amine	12055
@NP	BDA ; 10,000 kDa molecular mass	12070
@NP	BDA	12070
@NP	10,000 kDa molecular mass	12075
@NP	10,000 kDa	12075
@NP	molecular mass	12086
@NP	25 % in 0.5 % dimethylsulfoxide	12102
@NP	25 %	12102
@NP	0.5 % dimethylsulfoxide	12109
@NP	Molecular Probes	12133
@NP	Eugene , OR	12151
@NP	Eugene	12151
@NP	OR	12159
@NP	the red nucleus	12197
@NP	a rate of 80 nl/min	12216
@NP	a rate	12216
@NP	80 nl/min	12226
@NP	5.9 mm caudal to bregma , 0.7 mm lateral to midline , and 7 mm deep	12259
@NP	5.9 mm caudal	12259
@NP	bregma	12276
@NP	0.7 mm lateral to midline	12284
@NP	0.7 mm lateral	12284
@NP	midline	12302
@NP	7 mm	12315
@NP	Total injection volume	12326
@NP	animal size	12361
@NP	0.5 -- 0.8 µl	12378
@NP	0.5	12378
@NP	0.8 µl	12382
@NP	the pipette	12394
@NP	place for 5 minutes	12418
@NP	place	12418
@NP	5 minutes	12428
@NP	injection	12444
@NP	Immunohistochemistry	12455
@NP	the end of the survival period	12479
@NP	the end	12479
@NP	the survival period	12490
@NP	animals	12511
@NP	an overdose of chloral hydrate -LRB- 100 mg/kg , i.p. -RRB-	12536
@NP	an overdose	12536
@NP	chloral hydrate -LRB- 100 mg/kg , i.p. -RRB-	12551
@NP	chloral hydrate	12551
@NP	100 mg/kg , i.p.	12568
@NP	100 mg/kg	12568
@NP	PBS	12618
@NP	phosphate buffered , 4 % paraformaldehyde -LRB- pH 7.4 -RRB-	12634
@NP	phosphate buffered	12634
@NP	phosphate	12634
@NP	4 % paraformaldehyde -LRB- pH 7.4 -RRB-	12654
@NP	4 % paraformaldehyde	12654
@NP	pH 7.4	12675
@NP	The cervical spinal cords	12684
@NP	4 % paraformaldehyde	12740
@NP	overnight	12760
@NP	12 % , 18 % , and 22 % sucrose in 0.1 M phosphate buffer over 3 days	12788
@NP	12 %	12788
@NP	18 %	12793
@NP	22 % sucrose in 0.1 M phosphate buffer over 3 days	12802
@NP	22 % sucrose	12802
@NP	0.1 M phosphate buffer over 3 days	12817
@NP	0.1 M phosphate buffer	12817
@NP	3 days	12845
@NP	isopentane over dry ice	12867
@NP	isopentane	12867
@NP	dry ice	12883
@NP	Cervical segments from C2 to C6	12892
@NP	Cervical segments	12892
@NP	C2 to C6	12915
@NP	C2	12915
@NP	C6	12921
@NP	20-micron longitudinal sections in the horizontal plane on a cryostat	12938
@NP	20-micron longitudinal sections	12938
@NP	the horizontal plane on a cryostat	12973
@NP	the horizontal plane	12973
@NP	a cryostat	12997
@NP	-80 °C	13022
@NP	Frozen sections	13029
@NP	a slide warmer for 5 minutes	13060
@NP	a slide warmer	13060
@NP	5 minutes	13079
@NP	PBS , permeabilized for 1 hour in 0.1 % Triton-X 100 ,	13104
@NP	PBS	13104
@NP	1 hour in 0.1 % Triton-X	13127
@NP	1 hour	13127
@NP	0.1 % Triton-X	13137
@NP	100	13151
@NP	10 % goat serum for 20 minutes	13175
@NP	10 % goat serum	13175
@NP	20 minutes	13194
@NP	nonspecific binding	13216
@NP	David Carey , Penn State School of medicine -RRB-	13815
@NP	David	13815
@NP	Carey	13821
@NP	Penn State School of medicine	13828
@NP	Penn State School	13828
@NP	medicine	13849
@NP	rabbit anti-calcitonin gene-related peptide	13864
@NP	anti- CGRP	13909
@NP	1:4,000	13921
@NP	Sigma	13930
@NP	All primary antibodies	13938
@NP	4 °C	13987
@NP	Secondary antibodies -LRB- 1:200 , Jackson -RRB-	13992
@NP	Secondary antibodies	13992
@NP	1:200	14014
@NP	Jackson	14021
@NP	goat or donkey	14040
@NP	Alexa 594 , Alexa 488 , Alexa 350 , Cy3 , or aminomethylcoumarin	14073
@NP	Alexa 594	14073
@NP	Alexa 488	14084
@NP	Alexa 350	14095
@NP	Cy3	14106
@NP	aminomethylcoumarin	14114
@NP	AMCA	14135
@NP	1 hour at room temperature	14158
@NP	1 hour	14158
@NP	room temperature	14168
@NP	BDA	14186
@NP	Cy3	14214
@NP	AMCA-conjugated streptavidin -LRB- 1:200 , Jackson -RRB-	14222
@NP	AMCA-conjugated streptavidin	14222
@NP	1:200	14252
@NP	Jackson	14259
@NP	1 hour at room temperature	14280
@NP	1 hour	14280
@NP	room temperature	14290
@NP	Sections	14308
@NP	glycerol mounting medium -LRB- Sigma -RRB-	14339
@NP	glycerol mounting medium	14339
@NP	Sigma	14365
@NP	Vectashield -LRB- Vector Laboratories , Burlingame , CA -RRB-	14375
@NP	Vectashield	14375
@NP	Vector Laboratories	14388
@NP	Burlingame	14409
@NP	CA	14421
@NP	Image analysis and quantification Digital images	14426
@NP	Image analysis	14426
@NP	quantification Digital images	14445
@NP	an Axioplan 2 microscope -LRB- Zeiss , Jena , Germany -RRB-	14494
@NP	an Axioplan 2 microscope	14494
@NP	Zeiss	14520
@NP	Jena	14527
@NP	Germany	14533
@NP	a digital camera -LRB- QImaging , Burnaby , BC , Canada -RRB-	14543
@NP	a digital camera	14543
@NP	QImaging	14561
@NP	Burnaby	14571
@NP	BC , Canada	14580
@NP	Northern Eclipse software	14597
@NP	Empix Imaging	14624
@NP	Inc. , Mississauga	14639
@NP	ON , Canada	14658
@NP	Northern Eclipse and SigmaScan Pro -LRB- SPSS Inc. , Chicago , IL -RRB-	14698
@NP	Northern Eclipse	14698
@NP	SigmaScan Pro -LRB- SPSS Inc. , Chicago , IL -RRB-	14719
@NP	SigmaScan	14719
@NP	Pro -LRB- SPSS Inc. , Chicago , IL -RRB-	14729
@NP	Pro	14729
@NP	SPSS Inc.	14734
@NP	Chicago	14745
@NP	IL	14754
@NP	software	14758
@NP	Cavity size	14768
@NP	the area of cavity in 10 serial horizontal sections per animal	14808
@NP	the area	14808
@NP	cavity in 10 serial horizontal sections per animal	14820
@NP	cavity	14820
@NP	10 serial horizontal sections per animal	14830
@NP	10 serial horizontal sections	14830
@NP	animal	14864
@NP	a section-to-section interval of 100 µm	14876
@NP	a section-to-section interval	14876
@NP	100 µm	14909
@NP	the dorsal surface of the spinal cord	14928
@NP	the dorsal surface	14928
@NP	the spinal cord	14950
@NP	These 10 measurements	14967
@NP	the cumulative area of each animal	15011
@NP	the cumulative area	15011
@NP	each animal	15034
@NP	a relative measure of the lesion size	15049
@NP	a relative measure	15049
@NP	the lesion size	15071
@NP	A Student 's t test	15088
@NP	A Student 's	15088
@NP	treatment groups	15127
@NP	Rostral	15145
@NP	caudal migration of OECs	15153
@NP	caudal migration	15153
@NP	OECs	15173
@NP	the shortest distance	15194
@NP	each GFPpositive object -LRB- cell or group of cells -RRB-	15219
@NP	each GFPpositive object	15219
@NP	cell or group of cells	15244
@NP	cell or group	15244
@NP	cells	15261
@NP	a line drawn perpendicular to the dorsal columns , through the lesion epicenter	15273
@NP	a line	15273
@NP	the dorsal columns	15303
@NP	the lesion epicenter	15331
@NP	Measurements	15353
@NP	rostral and caudal migration -LRB- on either side of the injection site -RRB-	15369
@NP	rostral and caudal migration	15369
@NP	either side of the injection site	15402
@NP	either side	15402
@NP	the injection site	15417
@NP	each time point	15476
@NP	cells in the pia mater	15493
@NP	cells	15493
@NP	the pia mater	15502
@NP	Measurements	15531
@NP	100 images of three-to-five longitudinal sections per animal	15560
@NP	100 images	15560
@NP	three-to-five longitudinal sections per animal	15575
@NP	three-to-five longitudinal sections	15575
@NP	animal	15615
@NP	RESULTS	15624
@NP	1	15637
@NP	The number of transplanted LP-OECs	16144
@NP	The number	16144
@NP	transplanted LP-OECs	16158
@NP	2 to 60 days	16202
@NP	GFP-positive OECs	16220
@NP	five of nine animals 28 days	16255
@NP	five	16255
@NP	nine animals	16263
@NP	28 days	16276
@NP	transplantation and zero of three animals 60 days	16290
@NP	transplantation	16290
@NP	zero of three animals 60 days	16310
@NP	zero	16310
@NP	three animals 60 days	16318
@NP	three animals	16318
@NP	60 days	16332
@NP	transplantation	16346
@NP	Scale	16864
@NP	= 400 µm in a -LRB- applies to a -- h -RRB-	16874
@NP	= 400 µm	16874
@NP	400	16876
@NP	a	16886
@NP	a -- h	16900
@NP	h	16902
@NP	Fig. 2 .	16907
@NP	Fig.	16907
@NP	2	16912
@NP	Scale bars = 100 µm in a , b , g , i ; 200 µm in c -- f , h.	18898
@NP	Scale bars	18898
@NP	= 100 µm in a , b , g , i ; 200 µm in c -- f , h.	18909
@NP	= 100 µm in a , b , g , i	18909
@NP	= 100 µm	18909
@NP	100	18911
@NP	a , b , g , i	18921
@NP	a	18921
@NP	b	18923
@NP	g	18925
@NP	200 µm in c	18930
@NP	200 µm	18930
@NP	c	18940
@NP	f , h.	18942
@NP	f	18942
@NP	Fig. 3 .	18948
@NP	Fig.	18948
@NP	3	18953
@NP	Scale bars = 200 µm in a , c , e ; 50 µm in b , d , f.	20040
@NP	Scale bars	20040
@NP	= 200 µm in a , c , e ; 50 µm in b , d , f.	20051
@NP	= 200 µm in a , c , e	20051
@NP	=	20051
@NP	200 µm in a , c , e	20053
@NP	200 µm	20053
@NP	a , c ,	20063
@NP	a	20063
@NP	c	20065
@NP	50 µm in b , d , f.	20070
@NP	50 µm	20070
@NP	Fig. 4 .	20087
@NP	Fig.	20087
@NP	4	20092
@NP	Multiple axonal populations	20095
@NP	the olfactory ensheathing cell -LRB- OEC -RRB-	20146
@NP	the olfactory ensheathing cell	20146
@NP	OEC	20178
@NP	transplanted spinal cord lesion site	20184
@NP	transplanted spinal cord lesion	20184
@NP	site	20216
@NP	a	20222
@NP	control animals , 60 days after lesion	20228
@NP	control animals	20228
@NP	60 days after lesion	20245
@NP	60 days	20245
@NP	lesion	20259
@NP	axons	20267
@NP	the wall of the cavity	20284
@NP	the wall	20284
@NP	the cavity	20296
@NP	the lateral aspect of the lesion -LRB- n 3 -RRB-	20324
@NP	the lateral aspect	20324
@NP	the lesion -LRB- n 3 -RRB-	20346
@NP	the lesion	20346
@NP	n 3	20358
@NP	Scale bar	21231
@NP	250 µm	21243
@NP	a -LRB- applies to a , b , d , f , h , j -RRB-	21253
@NP	a	21253
@NP	a , b , d , f , h , j	21267
@NP	a	21267
@NP	b	21269
@NP	d	21271
@NP	f	21273
@NP	h	21275
@NP	j	21277
@NP	boxes = 350 µ wide areas of e	21281
@NP	boxes	21281
@NP	= 350 µ wide areas of e	21287
@NP	= 350 µ wide areas	21287
@NP	Fig. 5 .	21315
@NP	Fig.	21315
@NP	5	21320
@NP	Rostral interface between lesion area and unlesioned spinal cord	22602
@NP	Rostral interface	22602
@NP	lesion area and unlesioned spinal cord	22628
@NP	lesion area	22628
@NP	unlesioned spinal cord	22644
@NP	each image with an arrowhead	22680
@NP	each image	22680
@NP	an arrowhead	22696
@NP	An asterisk	22710
@NP	the center of the lesion site in each panel	22728
@NP	the center	22728
@NP	the lesion site in each panel	22742
@NP	the lesion site	22742
@NP	each panel	22761
@NP	Scale bars	22773
@NP	200 µm	22786
@NP	a -LRB- applies to a , c -- e , g , h -RRB- ; 50 µm in b ; 100 µm in f , i.	22796
@NP	a -LRB- applies to a , c -- e , g , h -RRB- ; 50 µm in b ; 100 µm in f ,	22796
@NP	a	22796
@NP	a , c -- e , g , h -RRB- ; 50 µm in b ; 100	22810
@NP	a	22810
@NP	c -- e , g , h -RRB- ; 50 µm in b ; 100	22812
@NP	c	22812
@NP	e , g , h -RRB- ; 50 µm in b ; 100	22815
@NP	g , h -RRB- ; 50 µm in b ; 100	22817
@NP	g , h -RRB-	22817
@NP	g	22817
@NP	; 50 µm	22821
@NP	50	22823
@NP	in b ; 100	22829
@NP	in	22829
@NP	b	22832
@NP	100	22835
@NP	f	22845
@NP	Fig. 6 .	22851
@NP	Fig.	22851
@NP	6	22856
@NP	Scale bars = 200 µm in a , e ; 100 µm in b -- d , f.	24412
@NP	Scale bars	24412
@NP	= 200 µm in a , e ; 100 µm in b -- d , f.	24423
@NP	= 200 µm in a , e	24423
@NP	=	24423
@NP	200 µm in a , e	24425
@NP	200 µm	24425
@NP	a ,	24435
@NP	a	24435
@NP	100 µm in b	24440
@NP	100 µm	24440
@NP	b	24450
@NP	d , f.	24452
@NP	d	24452
@NP	Fig. 7 .	24458
@NP	Fig.	24458
@NP	7	24463
@NP	Scale	25938
@NP	= 200 µm in a -LRB- applies to a -- h -RRB-	25948
@NP	= 200 µm	25948
@NP	200	25950
@NP	a	25960
@NP	a -- h	25974
@NP	h	25976
@NP	well-characterized , trackable OECs	25991
@NP	a series of cross-comparative transplantation studies	26049
@NP	a series	26049
@NP	cross-comparative transplantation studies	26061
@NP	we	26104
@NP	a novel approach	26123
@NP	LP-OECs -LRB- Au and Roskams , 2003 -RRB-	26162
@NP	LP-OECs	26162
@NP	Au and Roskams	26171
@NP	2003	26187
@NP	we	26200
@NP	homozygous mice	26222
@NP	eGFP driven by a CMV : betta-actin promoter	26249
@NP	eGFP	26249
@NP	a CMV	26264
@NP	betta-actin promoter	26270
@NP	We	26292
@NP	their retention of maximal eGFP expression in conjunction	26310
@NP	their retention	26310
@NP	maximal eGFP expression in conjunction	26329
@NP	maximal eGFP expression	26329
@NP	conjunction	26356
@NP	changes in antigenic and morphologic phenotype	26383
@NP	changes	26383
@NP	antigenic and morphologic phenotype	26394
@NP	successive passages -LRB- Okabe et al. , 1997 -RRB-	26438
@NP	successive passages	26438
@NP	Okabe	26459
@NP	et al. , 1997	26465
@NP	et al.	26465
@NP	1997	26473
@NP	All LP-OECs subsequently used in transplantation	26480
@NP	All LP-OECs	26480
@NP	transplantation	26513
@NP	24 hours	26541
@NP	transplantation	26557
@NP	98 -- 100 % pure OECs by both antigenic and morphologic analysis	26603
@NP	98	26603
@NP	100 % pure OECs by both antigenic and morphologic analysis	26606
@NP	100 % pure OECs	26606
@NP	both antigenic and morphologic analysis	26624
@NP	immunocytochemical analysis	26668
@NP	virtually all OECs	26697
@NP	readily detectable levels	26726
@NP	p75 -LRB- 97.9 ± 2.2 % -RRB- the cytoskeletal marker	26755
@NP	p75 -LRB- 97.9 ± 2.2 % -RRB-	26755
@NP	p75	26755
@NP	97.9 ± 2.2 %	26760
@NP	97.9 ±	26760
@NP	2.2 %	26767
@NP	the cytoskeletal marker	26773
@NP	S100betta -LRB- 99.5 ± 1.6 % -RRB- and diffuse	26798
@NP	S100betta -LRB- 99.5 ± 1.6 % -RRB-	26798
@NP	S100betta	26798
@NP	99.5 ± 1.6 %	26809
@NP	99.5 ±	26809
@NP	1.6 %	26816
@NP	diffuse	26826
@NP	lower expression of glial fibrillary acidic protein -LRB- GFAP -RRB-	26835
@NP	lower expression	26835
@NP	glial fibrillary acidic protein -LRB- GFAP -RRB-	26855
@NP	glial fibrillary acidic protein	26855
@NP	GFAP	26888
@NP	addition	26897
@NP	significant eGFP fluorescence	26909
@NP	No significant differences in morphology or antigenicity	26940
@NP	No significant differences	26940
@NP	morphology or antigenicity	26970
@NP	LP-OECs cultured fresh	27019
@NP	LP-OECs	27019
@NP	three times -LRB- i.e. , at 4 DIV , 8 DIV , and 12 DIV -RRB-	27055
@NP	i.e. , at 4 DIV , 8 DIV , and 12 DIV	27068
@NP	i.e.	27068
@NP	4 DIV , 8 DIV	27077
@NP	4 DIV	27077
@NP	8 DIV	27084
@NP	12 DIV	27095
@NP	those	27118
@NP	9 DIV	27137
@NP	four times -LRB- data not shown ; Au and Roskams , 2003 -RRB-	27156
@NP	four	27156
@NP	times -LRB- data not shown ; Au and Roskams , 2003 -RRB-	27161
@NP	times	27161
@NP	data not shown ; Au and Roskams , 2003	27168
@NP	data not shown	27168
@NP	data	27168
@NP	Au and Roskams , 2003	27184
@NP	Au and Roskams	27184
@NP	2003	27200
@NP	LP-OECs	27207
@NP	cavity formation	27236
@NP	limited migration and survival	27269
@NP	the spinal cord	27303
@NP	All initial transplantation experiments of mouse LPOECs	27319
@NP	All initial transplantation experiments	27319
@NP	mouse LPOECs	27362
@NP	a rat lesion	27393
@NP	the rat post-lesion spinal cord pathology	27414
@NP	the rat	27414
@NP	post-lesion spinal cord pathology	27422
@NP	the most common features of spinal cord pathology reported in human SCI	27465
@NP	the most common features	27465
@NP	spinal cord pathology reported in human SCI	27493
@NP	spinal cord pathology	27493
@NP	human SCI	27527
@NP	addition	27541
@NP	testing LP-OEC efficacy in the rat	27551
@NP	testing LP-OEC efficacy	27551
@NP	the rat	27578
@NP	us	27594
@NP	this repair strategy	27617
@NP	others being tested within our laboratories	27643
@NP	others	27643
@NP	our laboratories	27670
@NP	all of the other laboratories transplanting OB-OECs into rat SCI	27696
@NP	all	27696
@NP	the other laboratories transplanting OB-OECs into rat SCI	27703
@NP	the other laboratories	27703
@NP	OB-OECs	27740
@NP	rat SCI	27753
@NP	This strategy	27762
@NP	us	27792
@NP	cross-species transplantation of LP-OECs into a CNS environment	27806
@NP	cross-species transplantation	27806
@NP	LP-OECs into a CNS environment	27839
@NP	LP-OECs	27839
@NP	a CNS environment	27852
@NP	a feasible clinical approach	27879
@NP	the context of an appropriate immunosuppression paradigm	27911
@NP	the context	27911
@NP	an appropriate immunosuppression paradigm	27926
@NP	A total of 75,000 -- 150,000 LP-OECs from passages 3 -- 5	27969
@NP	A total of 75,000 -- 150,000 LP-OECs from passages	27969
@NP	A total of 75,000	27969
@NP	A total	27969
@NP	75,000	27980
@NP	150,000 LP-OECs from passages	27987
@NP	150,000 LP-OECs	27987
@NP	passages	28008
@NP	3 -- 5	28017
@NP	the site	28053
@NP	an acute lesion	28065
@NP	the dorsolateral funiculus in immune-suppressed adult male Sprague-Dawley rats	28084
@NP	the dorsolateral funiculus	28084
@NP	immune-suppressed adult male Sprague-Dawley rats	28114
@NP	Horizontal sections through the lesion site	28164
@NP	Horizontal sections	28164
@NP	the lesion site	28192
@NP	lesion volume	28233
@NP	cavity formation	28248
@NP	migration of transplanted cells -LRB- Fig. 1 -RRB-	28270
@NP	migration	28270
@NP	transplanted cells -LRB- Fig. 1 -RRB-	28283
@NP	transplanted cells	28283
@NP	Fig. 1	28303
@NP	control rats -LRB- DMEM/F12 alone -RRB-	28315
@NP	control rats	28315
@NP	DMEM/F12	28329
@NP	a cavity	28346
@NP	the site of injury	28365
@NP	the site	28365
@NP	injury	28377
@NP	the first week -LRB- Fig. 1a , c -RRB-	28391
@NP	the first week	28391
@NP	Fig. 1a , c	28407
@NP	Fig. 1a	28407
@NP	c	28415
@NP	rats	28448
@NP	lesion but no medium	28458
@NP	lesion	28458
@NP	no medium	28469
@NP	Tetzlaff , unpublished observation -RRB- .	28483
@NP	Tetzlaff	28483
@NP	observation	28505
@NP	The size of the cavity	28519
@NP	The size	28519
@NP	the cavity	28531
@NP	28 days	28557
@NP	maximal diameters of 0.5 to 1 mm -LRB- Fig. 1e , g -RRB-	28575
@NP	maximal diameters	28575
@NP	0.5 to 1 mm -LRB- Fig. 1e , g -RRB-	28596
@NP	0.5 to 1 mm	28596
@NP	Fig. 1e , g	28609
@NP	Fig. 1e	28609
@NP	g	28617
@NP	contrast	28624
@NP	cavity formation	28634
@NP	reduced -LRB- and usually absent -RRB-	28669
@NP	reduced	28669
@NP	animals that received OEC injections -LRB- Fig. 1b , d , f , h -RRB-	28701
@NP	animals	28701
@NP	OEC injections	28723
@NP	Fig. 1b , d , f , h	28739
@NP	Fig. 1b	28739
@NP	d	28747
@NP	f	28749
@NP	h	28751
@NP	Measurement of cavity area in horizontal sections of the spinal cord	28755
@NP	Measurement	28755
@NP	cavity area in horizontal sections of the spinal cord	28770
@NP	cavity area	28770
@NP	horizontal sections of the spinal cord	28785
@NP	horizontal sections	28785
@NP	the spinal cord	28808
@NP	a more than 99 % reduction -LRB- P < 0.001 -RRB-	28833
@NP	a more than 99 % reduction	28833
@NP	P < 0.001	28860
@NP	P	28860
@NP	< 0.001	28862
@NP	<	28862
@NP	0.001	28864
@NP	day 28	28874
@NP	lesion	28887
@NP	rats	28897
@NP	LP-OEC transplants	28920
@NP	the average cavity area in control rats	28946
@NP	the average cavity area	28946
@NP	control rats	28973
@NP	0.735 ± 0.293 mm2	28990
@NP	0.735 ±	28990
@NP	0.293 mm2	28998
@NP	animals	29016
@NP	OECs , 0.01 ± 0.004 mm2	29038
@NP	OECs	29038
@NP	0.01 ± 0.004 mm2	29044
@NP	0.01	29044
@NP	± 0.004 mm2	29049
@NP	minimal cavity formation by 28 days after OEC transplantation	29070
@NP	minimal cavity formation	29070
@NP	28 days after OEC transplantation	29098
@NP	28 days	29098
@NP	OEC transplantation	29112
@NP	the survival and migration of OECs in the spinal cord	29133
@NP	the survival and migration	29133
@NP	OECs in the spinal cord	29163
@NP	OECs	29163
@NP	the spinal cord	29171
@NP	2 to 28 days	29201
@NP	GFP	29224
@NP	a stable genetic marker	29231
@NP	survival and migration of the injected OECs	29265
@NP	survival and migration	29265
@NP	the injected OECs	29291
@NP	GFP-positive OECs	29310
@NP	the center of the lesion site 2 days	29357
@NP	the center	29357
@NP	the lesion site	29371
@NP	2 days	29387
@NP	transplantation	29400
@NP	migratory streams of OECs	29421
@NP	migratory streams	29421
@NP	OECs	29442
@NP	the host tissue	29471
@NP	700 m	29493
@NP	the lesion epicenter -LRB- Fig. 1b -RRB-	29505
@NP	the lesion epicenter	29505
@NP	Fig. 1b	29527
@NP	7 days	29540
@NP	these migratory OEC channels	29548
@NP	the lesion center into the host tissue -LRB- Fig. 1d -RRB-	29613
@NP	the lesion center	29613
@NP	the host tissue -LRB- Fig. 1d -RRB-	29636
@NP	the host tissue	29636
@NP	Fig. 1d	29653
@NP	28 days	29670
@NP	GFP-positive OECs	29679
@NP	more than 400 microns	29719
@NP	lesion epicenter -LRB- Fig 1f , i -RRB-	29751
@NP	lesion epicenter	29751
@NP	Fig 1f	29769
@NP	i	29776
@NP	GFPpositive OECs	29780
@NP	five	29811
@NP	nine of the injected rats surviving 28 days	29819
@NP	nine	29819
@NP	the injected rats surviving 28 days	29827
@NP	the injected rats	29827
@NP	28 days	29855
@NP	none -LRB- 0 of 3 -RRB- of the rats surviving 60 days	29870
@NP	none -LRB- 0 of 3 -RRB-	29870
@NP	none	29870
@NP	0 of 3	29876
@NP	0	29876
@NP	3	29881
@NP	the rats surviving 60 days	29887
@NP	the rats	29887
@NP	60 days	29906
@NP	We	29915
@NP	an anti-GFP antibody amplification detection approach	29928
@NP	potential down-regulation of GFP	29997
@NP	potential down-regulation	29997
@NP	GFP	30026
@NP	these results	30035
@NP	those for endogenous GFP fluorescence , -LRB- data not shown -RRB-	30059
@NP	those	30059
@NP	endogenous GFP fluorescence	30069
@NP	data not shown	30099
@NP	data	30099
@NP	7 to 60 days after lesion	30121
@NP	7 to 60 days	30121
@NP	lesion	30140
@NP	strongly autofluorescent -LRB- GFPnegative -RRB- cells	30148
@NP	macrophages	30211
@NP	the lesion site	30240
@NP	the degenerating dorsolateral funiculus	30280
@NP	several millimeters	30320
@NP	the lesion center	30345
@NP	medium - and cell-injected animals -LRB- Fig. 1g , h -RRB-	30371
@NP	medium - and cell-injected animals	30371
@NP	Fig. 1g , h	30406
@NP	Fig. 1g	30406
@NP	h	30414
@NP	the surprising loss of eGFPexpressing OECs compared with the persistence of p75	30424
@NP	the surprising loss	30424
@NP	OECs	30462
@NP	the persistence of p75	30481
@NP	the persistence	30481
@NP	p75	30500
@NP	positive or dye-labeled OECs reported by others	30505
@NP	positive or dye-labeled OECs	30505
@NP	others	30546
@NP	we	30554
@NP	the possibility that our transplanted OECs	30564
@NP	the possibility	30564
@NP	our transplanted OECs	30585
@NP	eGFP	30621
@NP	immunohistochemistry for the common OEC marker	30630
@NP	immunohistochemistry	30630
@NP	the common OEC marker	30655
@NP	the low affinity nerve growth factor	30678
@NP	p75	30716
@NP	a polyclonal antibody recognizing both rat and mouse p75	30727
@NP	a polyclonal antibody	30727
@NP	rat and mouse p75	30766
@NP	amplification immunohistochemistry of eGFP	30790
@NP	amplification immunohistochemistry	30790
@NP	eGFP	30828
@NP	28 days after lesion	30837
@NP	28 days	30837
@NP	lesion	30851
@NP	a dense network	30859
@NP	p75-expressing cells -LRB- similar to that reported by others -RRB-	30878
@NP	p75-expressing cells	30878
@NP	similar to that reported by others	30900
@NP	similar	30900
@NP	that	30911
@NP	others	30928
@NP	NF200-positive axons	30952
@NP	the center of the lesion site	30991
@NP	the center	30991
@NP	the lesion site	31005
@NP	a pattern	31024
@NP	the distribution of eGFP-positive cells -LRB- data not shown -RRB-	31062
@NP	the distribution	31062
@NP	eGFP-positive cells	31082
@NP	data not shown	31103
@NP	data	31103
@NP	OEC transplantation	31120
@NP	Schwann cell invasion	31149
@NP	the lesion site	31174
@NP	the conundrum of a significant population of p75-positive/eGFP-negative cells	31201
@NP	the conundrum	31201
@NP	a significant population of p75-positive/eGFP-negative cells	31218
@NP	a significant population	31218
@NP	p75-positive/eGFP-negative cells	31246
@NP	the lesion site at 28 days	31293
@NP	the lesion site	31293
@NP	28 days	31312
@NP	lesion	31326
@NP	we	31334
@NP	the presence of transplanted OECs	31352
@NP	the presence	31352
@NP	transplanted OECs	31368
@NP	cells -- such as peripheral host Schwann cells --	31427
@NP	cells	31427
@NP	peripheral host Schwann cells	31441
@NP	the formation of a new transitional zone -LRB- reviewed in Fraher , 1999 -RRB-	31516
@NP	the formation	31516
@NP	a new transitional zone -LRB- reviewed in Fraher , 1999 -RRB-	31533
@NP	a new transitional zone	31533
@NP	Fraher , 1999	31570
@NP	Fraher	31570
@NP	1999	31578
@NP	Horizontal tissue sections through the lesion site	31585
@NP	Horizontal tissue sections	31585
@NP	the lesion site	31620
@NP	endogenous -LRB- GFAP , blue ; p75 , red -RRB-	31659
@NP	endogenous	31659
@NP	GFAP , blue ; p75 , red	31671
@NP	GFAP	31671
@NP	blue ; p75	31677
@NP	blue	31677
@NP	p75	31683
@NP	red	31688
@NP	transplanted -LRB- eGFP , green -RRB-	31697
@NP	transplanted	31697
@NP	eGFP , green	31711
@NP	eGFP	31711
@NP	green	31717
@NP	glial proteins -LRB- Fig. 2 -RRB-	31724
@NP	glial proteins	31724
@NP	Fig. 2	31740
@NP	A monoclonal antibody recognizing a rat-specific form of p75	31749
@NP	A monoclonal antibody	31749
@NP	a rat-specific form of p75	31783
@NP	a rat-specific form	31783
@NP	p75	31806
@NP	us	31818
@NP	host p75-expressing cells from the transplanted GFP-positive mouse OECs	31843
@NP	host p75-expressing cells	31843
@NP	the transplanted GFP-positive mouse OECs	31874
@NP	A significant population	31916
@NP	host-derived p75-positive cells resembling migrating Schwann cells	31944
@NP	host-derived p75-positive cells	31944
@NP	Schwann cells	31997
@NP	the center of the lesion site , as soon as 7 days after lesion	32028
@NP	the center of the lesion site	32028
@NP	the center	32028
@NP	the lesion site	32042
@NP	7 days after lesion	32070
@NP	7 days	32070
@NP	lesion	32083
@NP	transplanted GFPpositive OECs -LRB- Fig. 2a -RRB-	32128
@NP	transplanted GFPpositive OECs	32128
@NP	Fig. 2a	32159
@NP	times	32183
@NP	lesion	32195
@NP	Schwann cells	32216
@NP	the lesion center	32256
@NP	the demarcation of a perilesion boundary , in close proximity	32292
@NP	the demarcation	32292
@NP	a perilesion boundary	32311
@NP	close proximity	32337
@NP	GFAP-expressing astrocytes -LRB- Fig. 2b , d , e -RRB-	32356
@NP	GFAP-expressing astrocytes	32356
@NP	Fig. 2b	32384
@NP	d	32392
@NP	e	32394
@NP	all time points after 7 days	32401
@NP	all time points	32401
@NP	7 days	32423
@NP	rat p75-positive Schwann cells	32431
@NP	the lesion site	32483
@NP	the remaining OECs	32510
@NP	other glial cells -LRB- Fig. 2b , d , e -RRB-	32551
@NP	other glial cells	32551
@NP	Fig. 2b	32570
@NP	d	32578
@NP	e	32580
@NP	28 days after lesion	32587
@NP	28 days	32587
@NP	lesion	32601
@NP	transplanted OECs	32624
@NP	the center of the lesion site	32659
@NP	the center	32659
@NP	the lesion site	32673
@NP	Schwann cells	32704
@NP	the lesion site boundary in a pattern similar to the initial migratory channels	32729
@NP	the lesion site boundary	32729
@NP	a pattern similar to the initial migratory channels	32757
@NP	a pattern	32757
@NP	the initial migratory channels	32778
@NP	transplanted LP-OECs -LRB- Fig. 2f , g -RRB-	32822
@NP	transplanted LP-OECs	32822
@NP	Fig. 2f , g	32844
@NP	Fig. 2f	32844
@NP	g	32852
@NP	This boundary	32856
@NP	a laminin-rich substrate	32894
@NP	GFAP-positive astrocytes	32925
@NP	the spinal cord side	32964
@NP	Fig. 2h	33000
@NP	i	33008
@NP	the lesion boundary	33043
@NP	Fig. 2f , g	33064
@NP	Fig. 2f	33064
@NP	g	33072
@NP	The rat p75	33076
@NP	positive cells	33089
@NP	Schwann cells in subsequent experiments	33131
@NP	Schwann cells	33131
@NP	subsequent experiments	33148
@NP	the coincident identification	33174
@NP	a subpopulation	33207
@NP	cells	33226
@NP	the lesion core	33235
@NP	S100 that were additionally eGFP-negative and GFAP-negative	33262
@NP	S100	33262
@NP	data not shown	33323
@NP	data	33323
@NP	Astrocytic response to lesion	33340
@NP	Astrocytic response	33340
@NP	lesion	33363
@NP	the presence of LP-OECs and Schwann cells	33384
@NP	the presence	33384
@NP	LP-OECs and Schwann cells	33400
@NP	the dramatic reduction	33432
@NP	cavity formation at the lesion site	33458
@NP	cavity formation	33458
@NP	the lesion site	33478
@NP	we	33495
@NP	OECs	33508
@NP	the formation of a gliotic scar	33530
@NP	the formation	33530
@NP	a gliotic scar	33547
@NP	the lesion boundary	33565
@NP	the major barrier	33602
@NP	axonal regeneration	33623
@NP	spinal cord injury -LRB- Fawcett and Asher , 1999 -RRB-	33649
@NP	spinal cord injury	33649
@NP	Fawcett and Asher	33669
@NP	1999	33688
@NP	Schwann cells	33702
@NP	OECs	33717
@NP	the normal adult CNS	33745
@NP	astrocytes in the outer nerve fiber layer of the olfactory bulb	33771
@NP	astrocytes	33771
@NP	the outer nerve fiber layer of the olfactory bulb	33785
@NP	the outer nerve fiber layer	33785
@NP	the olfactory bulb	33816
@NP	the reactive astrocytic response	33857
@NP	some	33929
@NP	these mechanisms	33937
@NP	gliotic scarring	33964
@NP	SCI -LRB- Lakatos et al. , 2000 -RRB-	33984
@NP	SCI	33984
@NP	Lakatos	33989
@NP	et al. , 2000	33997
@NP	et al.	33997
@NP	2000	34005
@NP	immunohistochemistry for GFAP and chondroitin sulfate proteoglycans	34022
@NP	immunohistochemistry	34022
@NP	GFAP and chondroitin sulfate proteoglycans	34047
@NP	CSPGs	34091
@NP	scar formation	34109
@NP	the lesion site -LRB- Fig. 3 -RRB-	34127
@NP	the lesion site	34127
@NP	Fig. 3	34144
@NP	all control animals	34153
@NP	both cavity and scar formation	34186
@NP	cavity	34191
@NP	scar formation	34202
@NP	that previously reported	34228
@NP	that	34228
@NP	Fawcett and Asher , 1999 ; Steward et al. , 1999	34266
@NP	Fawcett and Asher , 1999 ; Steward et al.	34266
@NP	Fawcett and Asher , 1999	34266
@NP	Fawcett and Asher	34266
@NP	1999	34285
@NP	Steward et al.	34291
@NP	Steward	34291
@NP	et al.	34299
@NP	1999	34307
@NP	control rats	34317
@NP	the cavity wall	34331
@NP	multiple layers of tangentially oriented CSPG-rich deposits	34360
@NP	multiple layers	34360
@NP	tangentially oriented CSPG-rich deposits	34379
@NP	a dense zone of GFAP-positive reactive astrocytes -LRB- Fig. 3a , b -RRB-	34425
@NP	a dense zone	34425
@NP	GFAP-positive reactive astrocytes -LRB- Fig. 3a , b -RRB-	34441
@NP	GFAP-positive reactive astrocytes	34441
@NP	Fig. 3a , b	34476
@NP	Fig. 3a	34476
@NP	b	34484
@NP	contrast	34491
@NP	rats that received OEC transplants	34501
@NP	rats	34501
@NP	OEC transplants	34520
@NP	a broader , diffuse band of GFAP-positive astrocytes	34549
@NP	a broader , diffuse band	34549
@NP	GFAP-positive astrocytes	34576
@NP	the spinal cord	34604
@NP	the lesion site	34632
@NP	irregular finger-like projections	34669
@NP	the lesion center -LRB- Fig. 3c , d -RRB-	34721
@NP	the lesion center	34721
@NP	Fig. 3c , d	34740
@NP	Fig. 3c	34740
@NP	d	34748
@NP	These astrocyte-filled projections	34752
@NP	the channels	34807
@NP	Schwann cell-rich projections	34823
@NP	the lesion center	34868
@NP	Fig. 2	34895
@NP	the GFAP/CSPG-rich dense scar boundary seen in control animals	34920
@NP	the GFAP/CSPG-rich dense scar boundary	34920
@NP	control animals	34967
@NP	Figs. 2 and 3	34992
@NP	Figs. 2	34992
@NP	3	35004
@NP	CSPG expression	35008
@NP	the LP-OEC transplanted lesion site was diffuse and oriented	35031
@NP	the LP-OEC	35031
@NP	transplanted lesion site	35042
@NP	the laminin-rich channels	35113
@NP	CSPG-poor regions	35145
@NP	the laminin-rich channels	35170
@NP	gliosis and CSPG deposition	35226
@NP	the presence of OECs , and later Schwann cells , at the lesion site	35255
@NP	the presence	35255
@NP	OECs , and later Schwann cells ,	35271
@NP	OECs	35271
@NP	Schwann cells	35287
@NP	the lesion site	35305
@NP	astrocyte and CSPG deposition	35333
@NP	longitudinal and radial streams extending from the edge of the lesion	35368
@NP	longitudinal and radial streams	35368
@NP	the edge of the lesion	35415
@NP	the edge	35415
@NP	the lesion	35427
@NP	the formation of a characteristic dense scar barrier	35452
@NP	the formation	35452
@NP	a characteristic dense scar barrier	35469
@NP	fact	35509
@NP	an astrocytic barrier	35535
@NP	regeneration	35560
@NP	the realigned GFAP-positive astrocytes	35574
@NP	permissive	35622
@NP	axonal growth	35636
@NP	NF200-positive axons	35655
@NP	the lesion site	35707
@NP	the reorganized	35757
@NP	GFAP-positive astrocytes -LRB- Fig. 3e , f -RRB-	35782
@NP	GFAP-positive astrocytes	35782
@NP	Fig. 3e	35808
@NP	f	35816
@NP	the origin of these axons	35829
@NP	the origin	35829
@NP	these axons	35843
@NP	many	35875
@NP	the host / lesion interface -LRB- Fig. 3e -RRB-	35904
@NP	the host / lesion interface	35904
@NP	the host	35904
@NP	lesion interface	35914
@NP	Fig. 3e	35932
@NP	Multiple central and peripheral axons	35942
@NP	regenerate/sprout	35980
@NP	response to LP-OEC transplantation	36001
@NP	response	36001
@NP	LP-OEC transplantation	36013
@NP	this presumably more permissive glial environment	36057
@NP	axonal regeneration	36124
@NP	the lesion site	36165
@NP	we	36182
@NP	the presence of axons	36196
@NP	the presence	36196
@NP	axons	36212
@NP	a variety of neuronal markers	36229
@NP	a variety	36229
@NP	neuronal markers	36242
@NP	immunostaining for axonal antigens	36262
@NP	immunostaining	36262
@NP	axonal antigens	36281
@NP	Fig. 4	36298
@NP	we	36322
@NP	expression	36334
@NP	III-tubulin -LRB- IIIT ; neuron-specific tubulin -RRB-	36349
@NP	III-tubulin	36349
@NP	IIIT ; neuron-specific tubulin	36363
@NP	IIIT	36363
@NP	neuron-specific tubulin	36369
@NP	NF200 , 5HT , TH , and CGRP	36395
@NP	control animals	36424
@NP	axons	36441
@NP	the wall	36472
@NP	the cavity	36484
@NP	the lateral aspect of the lesion -LRB- Fig. 4a -RRB-	36528
@NP	the lateral aspect	36528
@NP	the lesion -LRB- Fig. 4a -RRB-	36550
@NP	the lesion	36550
@NP	Fig. 4a	36562
@NP	GFP-positive OECs	36581
@NP	60 days	36630
@NP	all rats that had received OEC injections	36639
@NP	all rats	36639
@NP	OEC injections	36666
@NP	robust growth of axons	36688
@NP	robust growth	36688
@NP	axons	36705
@NP	the lesion site -LRB- Fig. 4b -- k -RRB-	36716
@NP	the lesion site	36716
@NP	Fig. 4b -- k	36733
@NP	Fig. 4b	36733
@NP	k	36741
@NP	Axons occupying the lesion site	36745
@NP	Axons	36745
@NP	the lesion site	36761
@NP	diameter	36806
@NP	NF200 and IIIT -LRB- Fig. 4b -- e -RRB-	36831
@NP	NF200 and IIIT	36831
@NP	Fig. 4b -- e	36848
@NP	Fig. 4b	36848
@NP	e	36856
@NP	Sprouting axons at the lesion center	36860
@NP	Sprouting axons	36860
@NP	the lesion center	36879
@NP	both the CNS and PNS	36913
@NP	expression of 5HT , TH , and CGRP -LRB- Fig. 4f -- k -RRB-	36951
@NP	expression	36951
@NP	5HT , TH , and CGRP -LRB- Fig. 4f -- k -RRB-	36965
@NP	5HT , TH , and CGRP	36965
@NP	Fig. 4f -- k	36984
@NP	Fig. 4f	36984
@NP	k	36993
@NP	The orientation of axons in the lesion site	36997
@NP	The orientation	36997
@NP	axons in the lesion site	37016
@NP	axons	37016
@NP	the lesion site	37025
@NP	their site of origin	37063
@NP	their site	37063
@NP	origin	37077
@NP	central axons	37090
@NP	a bias	37113
@NP	an axis	37123
@NP	the dorsal columns and peripheral axons running laterally across the lesion site	37148
@NP	the dorsal columns	37148
@NP	peripheral axons running laterally across the lesion site	37171
@NP	peripheral axons	37171
@NP	the lesion site	37213
@NP	IIIT-positive axons	37231
@NP	the center of the OEC-treated lesion site -LRB- Fig. 4b , c -RRB-	37280
@NP	the center	37280
@NP	the OEC-treated lesion site -LRB- Fig. 4b , c -RRB-	37294
@NP	the OEC-treated lesion site	37294
@NP	Fig. 4b , c	37323
@NP	Fig. 4b	37323
@NP	c	37331
@NP	Substantial projections , presumably from the brainstem , expressing 5HT and TH	37335
@NP	Substantial projections , presumably from the brainstem ,	37335
@NP	Substantial projections	37335
@NP	the brainstem	37376
@NP	5HT and TH	37402
@NP	a typical beaded axonal staining pattern	37423
@NP	the glia-rich lesion site	37487
@NP	numerous instances	37517
@NP	all animals examined	37540
@NP	all animals	37540
@NP	these axons	37562
@NP	the caudal lesion -- host interface -LRB- Fig. 4g , i , arrows -RRB-	37592
@NP	the caudal lesion	37592
@NP	host interface -LRB- Fig. 4g , i , arrows -RRB-	37610
@NP	host interface	37610
@NP	Fig. 4g , i , arrows	37626
@NP	Fig. 4g	37626
@NP	i	37634
@NP	arrows	37637
@NP	several millimeters	37666
@NP	Lateral profiles of sensory afferent axons expressing CGRP	37696
@NP	Lateral profiles	37696
@NP	sensory afferent axons expressing CGRP	37716
@NP	sensory afferent axons	37716
@NP	CGRP	37750
@NP	the OEC-treated lesion site -LRB- Fig. 4k -RRB-	37784
@NP	the OEC-treated lesion site	37784
@NP	Fig. 4k	37813
@NP	axonal regeneration	37832
@NP	the rubrospinal axons	37867
@NP	the distal cord	37913
@NP	this stage in the analysis	37932
@NP	this stage	37932
@NP	the analysis	37946
@NP	it	37960
@NP	transplanted mouse LP-OECs	37978
@NP	the appar	38027
@NP	ent hostility of the rat lesion site	38038
@NP	ent hostility	38038
@NP	the rat lesion site	38055
@NP	cavity and scar barrier formation	38089
@NP	extensive in-growth of axons of several different phenotypes	38151
@NP	extensive in-growth	38151
@NP	axons of several different phenotypes	38174
@NP	axons	38174
@NP	several different phenotypes	38183
@NP	the lesion center	38217
@NP	Figs. 1 -- 4	38236
@NP	Figs. 1	38236
@NP	4	38244
@NP	the NF200-positive axonal in-growth	38264
@NP	regeneration of the axotomized rubrospinal tract in response	38322
@NP	regeneration	38322
@NP	the axotomized rubrospinal tract in response	38338
@NP	the axotomized rubrospinal tract	38338
@NP	response	38374
@NP	OEC transplantation	38386
@NP	we	38407
@NP	the tract	38432
@NP	BDA in the vicinity of the right red nucleus 1 week	38455
@NP	BDA	38455
@NP	the vicinity of the right red nucleus 1 week	38462
@NP	the vicinity	38462
@NP	the right red nucleus	38478
@NP	1 week	38500
@NP	tracts -LRB- Fig. 5 -RRB-	38544
@NP	tracts	38544
@NP	Fig. 5	38552
@NP	control rats	38564
@NP	rubrospinal axons	38578
@NP	rostral	38614
@NP	the border of the cavity	38625
@NP	the border	38625
@NP	the cavity	38639
@NP	7 days	38650
@NP	injury	38663
@NP	Fig. 5a	38671
@NP	some of these axons	38681
@NP	some	38681
@NP	these axons	38689
@NP	a highly random path characteristic of growing axonal sprouts	38709
@NP	a highly random path characteristic	38709
@NP	growing axonal sprouts	38748
@NP	most axons	38777
@NP	morphologic characteristics of end-bulbs -LRB- Fig. 5b -RRB-	38798
@NP	morphologic characteristics	38798
@NP	end-bulbs -LRB- Fig. 5b -RRB-	38829
@NP	end-bulbs	38829
@NP	Fig. 5b	38840
@NP	rats that received LP-OEC transplants	38853
@NP	rats	38853
@NP	LP-OEC transplants	38872
@NP	fewer axons	38892
@NP	the rostral edge of the injury site	38927
@NP	the rostral edge	38927
@NP	the injury site	38947
@NP	none	38968
@NP	the OEC transplant	38987
@NP	7 days -LRB- Fig. 5c -RRB-	39009
@NP	7 days	39009
@NP	Fig. 5c	39017
@NP	The bulk of the rubrospinal tract	39027
@NP	The bulk	39027
@NP	the rubrospinal tract	39039
@NP	300 m rostral	39067
@NP	the lesion center	39085
@NP	control animals	39106
@NP	short 500 µm rostral	39134
@NP	500	39140
@NP	the lesion center	39158
@NP	OEC transplantation	39181
@NP	days 28 and 60	39205
@NP	many BDA-filled rubrospinal axons in control animals	39221
@NP	many BDA-filled rubrospinal axons	39221
@NP	control animals	39258
@NP	proximity to the rostral edge of the cavity	39288
@NP	proximity	39288
@NP	the rostral edge of the cavity	39301
@NP	the rostral edge	39301
@NP	the cavity	39321
@NP	the lesion -LRB- Fig. 5d , g -RRB-	39367
@NP	the lesion	39367
@NP	Fig. 5d , g	39379
@NP	Fig. 5d	39379
@NP	g	39387
@NP	OEC-treated rats	39394
@NP	the majority of the rubrospinal axons	39412
@NP	the majority	39412
@NP	the rubrospinal axons	39428
@NP	several hundred microns proximal to lesion -LRB- e.g. , Fig. 5e -RRB-	39456
@NP	several hundred microns	39456
@NP	lesion -LRB- e.g. , Fig. 5e -RRB-	39492
@NP	lesion	39492
@NP	e.g. , Fig. 5e	39500
@NP	e.g.	39500
@NP	Fig. 5e	39506
@NP	28 days after lesion	39519
@NP	28 days	39519
@NP	lesion	39533
@NP	some rubrospinal axons	39541
@NP	the center of the lesion occupied by OECs and Schwann cells -LRB- Fig. 5f -RRB-	39580
@NP	the center	39580
@NP	the lesion occupied by OECs and Schwann cells -LRB- Fig. 5f -RRB-	39594
@NP	the lesion	39594
@NP	OECs and Schwann cells -LRB- Fig. 5f -RRB-	39617
@NP	OECs and Schwann cells	39617
@NP	Fig. 5f	39641
@NP	Sprouting rubrospinal axons	39651
@NP	the center	39702
@NP	the lesion at 60 days , -LRB- i.e. , after LP-OECs could no longer be detected	39716
@NP	the lesion at 60 days , -LRB- i.e. ,	39716
@NP	the lesion at 60 days ,	39716
@NP	the lesion	39716
@NP	60 days ,	39730
@NP	i.e.	39740
@NP	LP-OECs	39752
@NP	Fig. 5h , i	39789
@NP	Fig. 5h	39789
@NP	We	39801
@NP	rubrospinal axons	39819
@NP	the caudal lesion -- host interface at any time ,	39848
@NP	the caudal lesion	39848
@NP	host interface at any time	39867
@NP	host interface	39867
@NP	any time	39885
@NP	control	39905
@NP	OEC-injected animals	39919
@NP	STIMULATION OF ANGIOGENESIS BY	39941
@NP	STIMULATION	39941
@NP	ANGIOGENESIS BY	39956
@NP	LP-OECS	39985
@NP	SUPPORT REGENERATION	40026
@NP	the `` channels ''	40058
@NP	glial cells	40093
@NP	axons	40119
@NP	the lesion site	40128
@NP	sites of local angiogenesis	40160
@NP	sites	40160
@NP	local angiogenesis	40169
@NP	we	40189
@NP	glial and neuronal marker detection	40201
@NP	testing	40242
@NP	the formation of new vasculature	40254
@NP	the formation	40254
@NP	new vasculature	40271
@NP	an antibody recognizing RECA-1 -LRB- Fig. 6 -RRB-	40292
@NP	an antibody	40292
@NP	RECA-1 -LRB- Fig. 6 -RRB-	40316
@NP	RECA-1	40316
@NP	Fig. 6	40324
@NP	28 days after LP-OEC transplantation	40336
@NP	28 days	40336
@NP	LP-OEC transplantation	40350
@NP	RECA-1 -- positive blood vessels	40374
@NP	RECA-1	40374
@NP	positive blood vessels	40382
@NP	the lesion site	40416
@NP	the laminin-rich spinal cord interface	40452
@NP	course	40494
@NP	the lesion core	40514
@NP	they	40536
@NP	direct contact with both GFP-positive LP-OECs -LRB- Fig. 6a , b -RRB-	40549
@NP	direct contact	40549
@NP	both GFP-positive LP-OECs -LRB- Fig. 6a , b -RRB-	40569
@NP	both GFP-positive LP-OECs	40569
@NP	Fig. 6a , b	40596
@NP	Fig. 6a	40596
@NP	b	40604
@NP	rat p75-positive/p200	40635
@NP	positive Schwann cells -LRB- Fig. 6c , d -RRB-	40658
@NP	positive Schwann cells	40658
@NP	Fig. 6c , d	40682
@NP	Fig. 6c	40682
@NP	d	40690
@NP	Axons extending into the lesion center	40694
@NP	Axons	40694
@NP	the lesion center	40715
@NP	stream	40745
@NP	RECA-1 -- positive blood vessels	40773
@NP	RECA-1	40773
@NP	positive blood vessels	40780
@NP	direct contacts	40811
@NP	transplanted LP-OECs -LRB- Fig. 6e , f -RRB-	40832
@NP	transplanted LP-OECs	40832
@NP	Fig. 6e	40854
@NP	f	40862
@NP	Allotransplantation	40866
@NP	OECs	40889
@NP	lesioned mouse spinal cord	40899
@NP	the many positive effects	40934
@NP	the cross-species transplantation of mouse LP-OECs	40974
@NP	the cross-species transplantation	40974
@NP	mouse LP-OECs	41011
@NP	immunosuppressed rat SCI	41030
@NP	it	41056
@NP	the limited survival of the LP-OECs and migration patterns	41080
@NP	the limited survival	41080
@NP	the LP-OECs and migration patterns	41104
@NP	most other reports	41184
@NP	vital	41209
@NP	labeling	41219
@NP	xenotransplantation	41244
@NP	The subsequent minimal regeneration of the rubrospinal tract	41265
@NP	The subsequent minimal regeneration	41265
@NP	the rubrospinal tract	41304
@NP	large part	41354
@NP	a localized acute immune response in a xenotransplant model	41368
@NP	a localized acute immune response	41368
@NP	a xenotransplant model	41405
@NP	we	41435
@NP	identical LP-OECs	41451
@NP	those	41472
@NP	rat experiments	41486
@NP	a dorsolateral funiculus crush site	41507
@NP	nontransgenic C57/Bl6 mice	41546
@NP	the main background strain used to generate the GFP-positive LPOECs	41574
@NP	the main background strain	41574
@NP	the GFP-positive LPOECs	41618
@NP	them	41655
@NP	the same immunosuppression paradigm used for the rats -LRB- Fig. 7 -RRB-	41665
@NP	the same immunosuppression paradigm	41665
@NP	the rats -LRB- Fig. 7 -RRB-	41710
@NP	the rats	41710
@NP	Fig. 7	41720
@NP	A similar migration to that seen in the rat	41729
@NP	A similar migration	41729
@NP	that seen in the rat	41752
@NP	that	41752
@NP	the rat	41765
@NP	contrast to the rat transplants	41795
@NP	contrast	41795
@NP	the rat transplants	41807
@NP	GFP-positive LP-OECs	41828
@NP	28 days	41871
@NP	injection	41885
@NP	a spinal cord lesion site	41900
@NP	all mice examined -LRB- seven of seven ; Fig. 7b -RRB-	41929
@NP	all mice	41929
@NP	seven of seven ; Fig. 7b	41948
@NP	seven	41948
@NP	seven ; Fig. 7b	41957
@NP	seven	41957
@NP	Fig. 7b	41964
@NP	the rat	41980
@NP	immunosuppression	42006
@NP	there	42025
@NP	a pronounced infiltration of autofluorescent mononuclear cells	42035
@NP	a pronounced infiltration	42035
@NP	autofluorescent mononuclear cells	42064
@NP	the lesion site -LRB- Fig. 7a , b -RRB-	42103
@NP	the lesion site	42103
@NP	Fig. 7a , b	42120
@NP	Fig. 7a	42120
@NP	b	42128
@NP	cavitation in this strain of mouse	42140
@NP	cavitation	42140
@NP	this strain of mouse	42154
@NP	this strain	42154
@NP	mouse	42169
@NP	Steward et al. , 1999	42199
@NP	Steward	42199
@NP	et al.	42207
@NP	1999	42215
@NP	the differences in lesion volume	42222
@NP	the differences	42222
@NP	lesion volume	42241
@NP	The zone of GFAP-positive reactive astrocytes surrounding the lesion	42274
@NP	The zone	42274
@NP	GFAP-positive reactive astrocytes surrounding the lesion	42286
@NP	GFAP-positive reactive astrocytes	42286
@NP	the lesion	42332
@NP	mice that had received GFP-positive LPOEC transplants	42378
@NP	mice	42378
@NP	GFP-positive LPOEC transplants	42401
@NP	the lesion border	42437
@NP	no indication of dense scar formation	42465
@NP	no indication	42465
@NP	dense scar formation	42482
@NP	the rat	42510
@NP	the infiltration of p75-positive Schwann cells	42519
@NP	the infiltration	42519
@NP	p75-positive Schwann cells	42539
@NP	transplantation of LP-OECs -LRB- Fig. 7c -- f -RRB-	42590
@NP	transplantation	42590
@NP	LP-OECs -LRB- Fig. 7c -- f -RRB-	42609
@NP	LP-OECs	42609
@NP	Fig. 7c -- f	42618
@NP	Fig. 7c	42618
@NP	f	42626
@NP	There	42630
@NP	a similar significant population	42640
@NP	NF200-positive axons	42676
@NP	the center of the lesion in the treated animals -LRB- Fig. 7f -RRB-	42719
@NP	the center	42719
@NP	the lesion in the treated animals -LRB- Fig. 7f -RRB-	42733
@NP	the lesion	42733
@NP	the treated animals -LRB- Fig. 7f -RRB-	42747
@NP	the treated animals	42747
@NP	Fig. 7f	42768
@NP	axons	42784
@NP	the scar boundary	42802
@NP	the lesion center	42845
@NP	the control group -LRB- Fig. 7e -RRB- DISCUSSION	42866
@NP	Fig. 7e	42885
@NP	GFP-expressing	42943
@NP	LPOECs transplanted into acute spinal cord injury sites	42959
@NP	LPOECs	42959
@NP	acute spinal cord injury sites	42984
@NP	rats	43018
@NP	mice	43027
@NP	several novel mechanistic insights	43039
@NP	OECs	43084
@NP	a unique environment to support regeneration	43096
@NP	regeneration	43128
@NP	These results	43142
@NP	LP-OECs	43169
@NP	great distances	43200
@NP	multiple distinct , novel , and beneficial effects on spinal cord regeneration	43224
@NP	multiple distinct , novel , and beneficial effects	43224
@NP	spinal cord regeneration	43276
@NP	this in a xenotransplantation paradigm	43318
@NP	this	43318
@NP	a xenotransplantation paradigm	43326
@NP	limited migration and short-term survival	43366
@NP	host spinal cord after transplantation	43411
@NP	host spinal cord	43411
@NP	transplantation	43434
@NP	LP-OECs	43451
@NP	cavity formation	43469
@NP	glial scar formation	43498
@NP	the invasion of host Schwann cells	43532
@NP	the invasion	43532
@NP	host Schwann cells	43548
@NP	a laminin-rich CNS microenvironment that stimulated extensive sprouting	43580
@NP	a laminin-rich CNS microenvironment	43580
@NP	axonal regeneration of multiple motor and sensory axons	43656
@NP	axonal regeneration	43656
@NP	multiple motor and sensory axons	43679
@NP	multiple motor	43679
@NP	sensory axons	43698
@NP	Migration patterns of LP-OECs The limited survival and migration of LP-OECs	43713
@NP	Migration patterns	43713
@NP	LP-OECs The limited survival and migration of LP-OECs	43735
@NP	LP-OECs The limited survival	43735
@NP	LP-OECs	43735
@NP	The limited survival	43743
@NP	migration of LP-OECs	43768
@NP	migration	43768
@NP	LP-OECs	43781
@NP	light	43812
@NP	previous transplantation studies	43821
@NP	survival and migration of bulb-derived OECs	43864
@NP	survival and migration	43864
@NP	bulb-derived OECs	43890
@NP	host spinal cord	43911
@NP	2 to 8 months	43932
@NP	Li	43947
@NP	et al. , 1998 ; Ramon - Cueto , 2000 ; Takami et al. , 2002	43950
@NP	et al.	43950
@NP	1998 ; Ramon - Cueto , 2000 ; Takami et al.	43958
@NP	1998 ; Ramon	43958
@NP	1998	43958
@NP	Ramon	43964
@NP	Cueto , 2000	43971
@NP	Cueto	43971
@NP	2000	43978
@NP	Takami et al.	43984
@NP	Takami	43984
@NP	et al.	43991
@NP	2002	43999
@NP	These differences	44006
@NP	inherent problems	44040
@NP	the use	44061
@NP	track cells	44088
@NP	distinct differences	44106
@NP	the adaptability of bulb-derived versus mucosa-derived OECs in the spinal cord	44130
@NP	the adaptability	44130
@NP	bulb-derived versus mucosa-derived OECs in the spinal cord	44150
@NP	bulb-derived	44150
@NP	mucosa-derived OECs in the spinal cord	44170
@NP	mucosa-derived OECs	44170
@NP	the spinal cord	44193
@NP	endogenous eGFP fluorescence	44219
@NP	the fate of the transplanted LP-OECs	44284
@NP	the fate	44284
@NP	the transplanted LP-OECs	44296
@NP	their migration	44322
@NP	a GFP filter	44372
@NP	the lowest magnification	44388
@NP	25	44424
@NP	migration routes delineated microscopically -LRB- Fig. 1 -RRB-	44434
@NP	migration routes	44434
@NP	Fig. 1	44479
@NP	an initial migration	44496
@NP	channels	44539
@NP	the host cord surrounding the lesion site	44553
@NP	the host cord	44553
@NP	the lesion site	44579
@NP	the persistence of mouse LP-OECs at the rat lesion site	44596
@NP	the persistence	44596
@NP	mouse LP-OECs at the rat lesion site	44615
@NP	mouse LP-OECs	44615
@NP	the rat lesion site	44632
@NP	LP-OECs	44669
@NP	28 to 60 days	44701
@NP	the rat spinal cord	44744
@NP	60 days	44767
@NP	transplantation	44781
@NP	mouse LP-OECs	44809
@NP	a mouse-lesion site	44845
@NP	the relatively poor survival of mouse LP-OECs	44866
@NP	the relatively poor survival	44866
@NP	mouse LP-OECs	44898
@NP	part	44936
@NP	an acute rejection response	44945
@NP	cells	44993
@NP	treatment with cyclosporin A.	45008
@NP	treatment	45008
@NP	cyclosporin A.	45023
@NP	LP-OECs	45053
@NP	OB-OECs to migrating through a CNS environment	45088
@NP	OB-OECs	45088
@NP	a CNS environment	45117
@NP	this reason	45140
@NP	rat OB-OECs transplanted into a similar rat lesion	45183
@NP	rat OB-OECs	45183
@NP	a similar rat lesion	45213
@NP	a similar limited migration pattern	45252
@NP	transplantation -LRB- Li et al. , 2003 -RRB-	45294
@NP	transplantation	45294
@NP	Li	45311
@NP	et al. , 2003	45314
@NP	et al.	45314
@NP	2003	45322
@NP	The majority	45329
@NP	published OEC transplant experiments	45345
@NP	more extensive migration and survival	45401
@NP	the fate	45476
@NP	transplanted OECs	45488
@NP	Ramon-Cueto and Nieto-Sampedro	45507
@NP	1994	45539
@NP	Ramon-Cueto	45545
@NP	et al. , 1998	45557
@NP	et al.	45557
@NP	1998	45565
@NP	Imaizumi et al. , 2000a , b	45571
@NP	Imaizumi	45571
@NP	et al. , 2000a , b	45580
@NP	et al.	45580
@NP	2000a	45588
@NP	b	45594
@NP	Ramon-Cueto et al. , 2000	45597
@NP	Ramon-Cueto	45597
@NP	et al. , 2000	45609
@NP	et al.	45609
@NP	2000	45617
@NP	Boruch et al. , 2001	45623
@NP	Boruch	45623
@NP	et al. , 2001	45630
@NP	et al.	45630
@NP	2001	45638
@NP	Lu et al. , 20012002	45644
@NP	Lu	45644
@NP	et al. , 20012002	45647
@NP	et al.	45647
@NP	20012002	45655
@NP	Verdu et al. , 2001	45665
@NP	Verdu	45665
@NP	et al. , 2001	45671
@NP	et al.	45671
@NP	2001	45679
@NP	Nash et al.	45685
@NP	Nash	45685
@NP	et al.	45690
@NP	2002	45698
@NP	These approaches	45705
@NP	potential diffusion	45746
@NP	the	45769
@NP	transplanted cells	45788
@NP	other cells	45853
@NP	Iwashita	45881
@NP	et al. , 2000	45890
@NP	et al.	45890
@NP	2000	45898
@NP	addition	45908
@NP	the habitual use	45918
@NP	p75 immunodetection	45938
@NP	transplanted OECs	45970
@NP	the spinal cord in vivo	45991
@NP	the spinal cord	45991
@NP	vivo	46010
@NP	the light	46036
@NP	our discovery of a significant population of endogenous Schwann cells	46049
@NP	our discovery	46049
@NP	a significant population of endogenous Schwann cells	46066
@NP	a significant population	46066
@NP	endogenous Schwann cells	46094
@NP	p75	46144
@NP	the spinal cord	46159
@NP	LP-OEC transplantation	46181
@NP	Figs. 2 , 6 ; Li et al. , 1997 , 1998 ; Takami et al. , 2002	46205
@NP	Figs. 2	46205
@NP	Figs.	46205
@NP	2	46211
@NP	6 ; Li et al.	46214
@NP	6	46214
@NP	Li et al.	46217
@NP	Li	46217
@NP	et al.	46220
@NP	1997	46228
@NP	1998 ; Takami et al. , 2002	46234
@NP	1998	46234
@NP	Takami et al. , 2002	46240
@NP	Takami	46240
@NP	et al. , 2002	46247
@NP	et al.	46247
@NP	2002	46255
@NP	LP-OECs	46262
@NP	cavity and scar formation	46279
@NP	It	46305
@NP	their limited survival after transplantation	46339
@NP	their limited survival	46339
@NP	transplantation	46368
@NP	LP-OECs	46385
@NP	the spinal cord lesion environment in several ways	46413
@NP	the spinal cord lesion environment	46413
@NP	several ways	46451
@NP	normal barriers	46478
@NP	regeneration	46497
@NP	One of the most dramatic results of OEC transplantation	46511
@NP	One	46511
@NP	the most dramatic results of OEC transplantation	46518
@NP	the most dramatic results	46518
@NP	OEC transplantation	46547
@NP	the lack of cavity at the lesion site -LRB- Figs. 1 , 2 -RRB-	46571
@NP	the lack	46571
@NP	cavity at the lesion site -LRB- Figs. 1 , 2 -RRB-	46583
@NP	cavity	46583
@NP	the lesion site -LRB- Figs. 1 , 2 -RRB-	46593
@NP	the lesion site	46593
@NP	Figs. 1	46610
@NP	2	46619
@NP	Cavities , such as those seen in control rats ,	46623
@NP	Cavities	46623
@NP	those seen in control rats	46641
@NP	those	46641
@NP	control rats	46655
@NP	a major obstacle	46684
@NP	axonal regeneration	46704
@NP	axons	46728
@NP	a growth substrate for elongation	46742
@NP	a growth substrate	46742
@NP	elongation	46765
@NP	cavities in rats	46785
@NP	cavities	46785
@NP	rats	46797
@NP	those in humans	46820
@NP	those	46820
@NP	humans	46829
@NP	their formation	46848
@NP	a significant step	46871
@NP	successful treatment of human SCI -LRB- reviewed in Schwab , 2002 -RRB-	46897
@NP	successful treatment	46897
@NP	human SCI	46921
@NP	Schwab , 2002	46944
@NP	Schwab	46944
@NP	2002	46952
@NP	7 days	46971
@NP	LP-OEC transplantation	46984
@NP	rat p75-positive host Schwann cells	47008
@NP	rat	47008
@NP	p75-positive host Schwann cells	47012
@NP	the core of the lesion	47056
@NP	the core	47056
@NP	the lesion	47068
@NP	the marginal zone of the cell transplant -LRB- Fig. 2 -RRB-	47099
@NP	the marginal zone	47099
@NP	the cell transplant -LRB- Fig. 2 -RRB-	47120
@NP	the cell transplant	47120
@NP	Fig. 2	47141
@NP	OECs	47153
@NP	the lesion core	47177
@NP	Schwann cells	47194
@NP	laminin-rich channels	47216
@NP	the host	47254
@NP	spinal cord , similar to those outlined by the early migrating OECs	47263
@NP	spinal cord	47263
@NP	those outlined by the early migrating OECs	47287
@NP	those	47287
@NP	the early migrating OECs	47305
@NP	Schwann cells	47340
@NP	lesioned spinal cord -LRB- Brook et al. , 1998 -RRB-	47388
@NP	lesioned spinal cord	47388
@NP	Brook	47410
@NP	et al. , 1998	47416
@NP	et al.	47416
@NP	1998	47424
@NP	their progress	47431
@NP	the hostile environment of the lesion site	47468
@NP	the hostile environment	47468
@NP	the lesion site	47495
@NP	they	47515
@NP	the control spinal cords showed very limited Schwann cell invasion	47562
@NP	the control	47562
@NP	spinal cords	47574
@NP	very limited Schwann cell invasion	47594
@NP	Figs. 2	47630
@NP	6	47639
@NP	we	47643
@NP	OECs	47660
@NP	a CNS environment	47678
@NP	migration and integration of infiltrating Schwann cells	47713
@NP	migration and integration	47713
@NP	Schwann cells	47755
@NP	Schwann cells	47770
@NP	the cellular substrate for successful regeneration in the PNS	47788
@NP	the cellular substrate	47788
@NP	successful regeneration in the PNS	47815
@NP	successful regeneration	47815
@NP	the PNS	47842
@NP	minichannels	47871
@NP	regeneration	47893
@NP	Martini , 1994 ; Fu and Gordon , 1997	47924
@NP	Martini	47924
@NP	1994 ; Fu and Gordon	47933
@NP	1994	47933
@NP	Fu and Gordon	47939
@NP	1997	47954
@NP	Schwann cell and peripheral nerve transplantation strategies	47961
@NP	Schwann cell	47961
@NP	peripheral nerve transplantation strategies	47978
@NP	considerable promise	48033
@NP	repair of a variety of SCI models	48057
@NP	repair	48057
@NP	a variety of SCI models	48067
@NP	a variety	48067
@NP	SCI models	48080
@NP	they	48097
@NP	the regeneration	48114
@NP	sensory , propriospinal , and brainstem spinal neurons	48134
@NP	brainstem	48162
@NP	Martin	48188
@NP	et al. , 19911996 ; Xu et al. , 1997	48195
@NP	et al.	48195
@NP	19911996 ; Xu et al.	48203
@NP	19911996	48203
@NP	Xu et al.	48213
@NP	Xu	48213
@NP	et al.	48216
@NP	1997	48224
@NP	addition	48234
@NP	several remyelination strategies -LRB- reviewed in Kocsis et al. , 2002 -RRB-	48265
@NP	several remyelination strategies	48265
@NP	Kocsis	48311
@NP	et al. , 2002	48318
@NP	et al.	48318
@NP	2002	48326
@NP	these cases	48345
@NP	the re-entry of regenerating axons from the Schwann cells	48358
@NP	the re-entry	48358
@NP	axons	48387
@NP	the Schwann cells	48398
@NP	the host spinal cord has been limited	48428
@NP	the host	48428
@NP	spinal cord	48437
@NP	Schwann cell transplantation	48467
@NP	OB-OEC grafts	48524
@NP	the spinal cord interface	48541
@NP	better axonal regeneration	48581
@NP	Schwann cell cables	48616
@NP	a transection -LRB- Ramon-Cueto et al. , 1998 ; Takami et al. , 2002 -RRB-	48639
@NP	a transection	48639
@NP	Ramon-Cueto	48654
@NP	et al. , 1998 ; Takami et al. , 2002	48666
@NP	et al.	48666
@NP	1998 ; Takami et al.	48674
@NP	1998	48674
@NP	Takami et al.	48680
@NP	Takami	48680
@NP	et al.	48687
@NP	2002	48695
@NP	a contusion model -LRB- Ramon-Cueto et al. , 1998 ; Takami et al. , 2002 -RRB-	48713
@NP	a contusion model	48713
@NP	Ramon-Cueto	48732
@NP	et al. , 1998 ; Takami et al. , 2002	48744
@NP	et al.	48744
@NP	1998 ; Takami et al.	48752
@NP	1998	48752
@NP	Takami et al.	48758
@NP	Takami	48758
@NP	et al.	48765
@NP	2002	48773
@NP	Our results	48780
@NP	lesions where host Schwann cells can access the lesion site	48810
@NP	lesions	48810
@NP	host Schwann cells	48824
@NP	the lesion site	48854
@NP	OECs	48871
@NP	them	48890
@NP	an environment	48906
@NP	both axonal growth and modification of the graft	48942
@NP	both axonal growth and modification	48942
@NP	the graft	48981
@NP	host glial interface	48991
@NP	The dense glial scar normally formed around the cavity of a spinal cord lesion	49013
@NP	The dense glial scar	49013
@NP	the cavity of a spinal cord lesion	49057
@NP	the cavity	49057
@NP	a spinal cord lesion	49071
@NP	a major barrier	49106
@NP	regeneration -LRB- reviewed in Fawcett , 2002 -RRB-	49125
@NP	regeneration	49125
@NP	Fawcett , 2002	49151
@NP	Fawcett	49151
@NP	2002	49160
@NP	the tight pericavity boundary characteristic of glial scar formation	49192
@NP	the tight pericavity boundary characteristic	49192
@NP	glial scar formation	49240
@NP	GFAP-positive astrocytes	49262
@NP	a wide , diffuse permeabilized matrix around the LP-OECs	49292
@NP	a wide , diffuse permeabilized matrix	49292
@NP	the LP-OECs	49336
@NP	the rostrocaudal channels formed by invading LP-OECs -LRB- Fig. 3 -RRB-	49364
@NP	the rostrocaudal channels	49364
@NP	LP-OECs -LRB- Fig. 3 -RRB-	49409
@NP	LP-OECs	49409
@NP	Fig. 3	49418
@NP	This astrocytic network	49427
@NP	finger-like projections	49465
@NP	the lesion center	49505
@NP	Schwann cells	49556
@NP	spinal tracts	49591
@NP	the distal lesion -- host interface	49614
@NP	the distal lesion	49614
@NP	host interface	49632
@NP	This organization	49648
@NP	the establishment of the developing PNS	49691
@NP	the establishment	49691
@NP	the developing PNS	49712
@NP	CNS transitional zone -LRB- Fraher , 1999 -RRB-	49731
@NP	CNS	49731
@NP	transitional zone -LRB- Fraher , 1999 -RRB-	49735
@NP	transitional zone	49735
@NP	Fraher , 1999	49754
@NP	Fraher	49754
@NP	1999	49762
@NP	Glial scar permeability	49769
@NP	the expression	49813
@NP	CSPGs	49831
@NP	neurite outgrowth	49883
@NP	OECtreated lesions	49909
@NP	McKeon et al. , 1995 ; Anderson et al. , 1998 ; Bradbury et al. , 2002	49929
@NP	McKeon	49929
@NP	et al. , 1995 ; Anderson et al. , 1998 ; Bradbury et al. , 2002	49936
@NP	et al. , 1995	49936
@NP	et al.	49936
@NP	1995	49944
@NP	Anderson et al. , 1998	49950
@NP	Anderson	49950
@NP	et al. , 1998	49959
@NP	et al.	49959
@NP	1998	49967
@NP	Bradbury et al. , 2002	49973
@NP	Bradbury	49973
@NP	et al. , 2002	49982
@NP	et al.	49982
@NP	2002	49990
@NP	CSPG production	50006
@NP	the pattern of CSPG deposition	50061
@NP	the pattern	50061
@NP	CSPG deposition	50076
@NP	diffuse deposits	50107
@NP	the lesion	50141
@NP	astrocytes	50175
@NP	the more tangential barriers of a dense scar	50197
@NP	the more tangential barriers	50197
@NP	a dense scar	50229
@NP	LP-OECs , astrocytes , and Schwann cells	50243
@NP	LP-OECs	50243
@NP	astrocytes	50252
@NP	Schwann cells	50268
@NP	a novel glial microenvironment Changes in local ECM composition and arrangement	50287
@NP	a novel glial microenvironment Changes	50287
@NP	local ECM composition and arrangement	50329
@NP	both astrocytes and their associated CSPGs	50381
@NP	both astrocytes	50381
@NP	their associated CSPGs	50401
@NP	neurite outgrowth -LRB- Ard et al. , 1991 ; Emerling and Lander , 1996 -RRB-	50467
@NP	neurite outgrowth -LRB- Ard et al.	50467
@NP	neurite outgrowth	50467
@NP	Ard et al.	50486
@NP	Ard	50486
@NP	et al.	50490
@NP	1991 ; Emerling and Lander , 1996 -RRB-	50498
@NP	1991	50498
@NP	Emerling and Lander , 1996	50504
@NP	Emerling	50504
@NP	Lander , 1996	50517
@NP	Lander	50517
@NP	1996	50525
@NP	The directed alignment	50532
@NP	astrocytes along laminin richchannels	50558
@NP	astrocytes	50558
@NP	laminin richchannels	50575
@NP	the OEC-treated lesion site	50611
@NP	the host tissue	50644
@NP	CSPG deposition	50675
@NP	at least part of the mechanism of OEC action	50714
@NP	at least part	50714
@NP	the mechanism of OEC action	50731
@NP	the mechanism	50731
@NP	OEC action	50748
@NP	permissive matrix	50777
@NP	the local environment	50819
@NP	inhibitory to supportive of regeneration	50846
@NP	inhibitory to supportive	50846
@NP	regeneration	50874
@NP	This finding	50888
@NP	the glial interrelationships	50909
@NP	clear boundaries	50963
@NP	limit	51001
@NP	the areas of direct interaction that OECs and astrocytes may have	51007
@NP	the areas	51007
@NP	direct interaction	51020
@NP	OECs and astrocytes	51044
@NP	Van Den Pol and Santarelli , 2003	51074
@NP	Van Den Pol and Santarelli	51074
@NP	2003	51102
@NP	invasion of host Schwann cells	51136
@NP	invasion	51136
@NP	host Schwann cells	51148
@NP	LP-OEC transplantation	51168
@NP	the groundwork	51206
@NP	a permissive PNS environment	51234
@NP	the site of SCI	51266
@NP	the site	51266
@NP	SCI	51278
@NP	this local environment	51286
@NP	reactive astrocytes and CSPGs	51310
@NP	significant barriers	51354
@NP	regeneration	51378
@NP	channels	51412
@NP	in-growth of multiple brainstem	51432
@NP	in-growth	51432
@NP	multiple brainstem	51445
@NP	spinal tracts	51464
@NP	Figs. 4	51479
@NP	7	51488
@NP	LP-OECs	51492
@NP	differential axonal sprouting	51507
@NP	regeneration	51541
@NP	The permissive environment created by LP-OEC transplantation	51554
@NP	The permissive environment	51554
@NP	LP-OEC transplantation	51592
@NP	in-growth	51627
@NP	a regeneration response	51641
@NP	both serotonin - and TH-positive axons -LRB- Fig. 4 -RRB-	51668
@NP	both serotonin	51668
@NP	TH-positive axons	51688
@NP	Fig. 4	51707
@NP	The growth	51716
@NP	5HT-positive axons in and through the lesion site observed in this study	51730
@NP	5HT-positive axons	51730
@NP	the lesion site observed in this study	51764
@NP	the lesion site	51764
@NP	this study	51792
@NP	i.e. , with transplantation of purified cultures of LP-OECs	51804
@NP	i.e.	51804
@NP	with transplantation of purified cultures of LP-OECs	51810
@NP	transplantation	51815
@NP	purified cultures of LP-OECs	51834
@NP	purified cultures	51834
@NP	LP-OECs	51855
@NP	that	51878
@NP	transplantation	51898
@NP	heterogeneous strips of olfactory mucosa -LRB- Lu et al. , 2001 -RRB-	51917
@NP	heterogeneous strips	51917
@NP	olfactory mucosa -LRB- Lu et al. , 2001 -RRB-	51941
@NP	olfactory mucosa	51941
@NP	Lu	51959
@NP	et al. , 2001	51962
@NP	et al.	51962
@NP	2001	51970
@NP	Serotonin and other biogenic amines	51977
@NP	Serotonin	51977
@NP	other biogenic amines	51991
@NP	rhythmic locomotor activity	52050
@NP	means of a central pattern generator	52093
@NP	means	52093
@NP	a central pattern generator	52102
@NP	cats and rodents -LRB- Gerin et al. , 1995 -RRB-	52134
@NP	cats and rodents	52134
@NP	Gerin	52152
@NP	et al. , 1995	52158
@NP	et al.	52158
@NP	1995	52166
@NP	a regeneration response in 5HT-positive axons	52179
@NP	a regeneration response	52179
@NP	5HT-positive axons	52206
@NP	the functional recovery	52260
@NP	an open field locomotion test -LRB- Lu et al. , 2002 -RRB-	52296
@NP	an open field locomotion test	52296
@NP	Lu	52327
@NP	et al. , 2002	52330
@NP	et al.	52330
@NP	2002	52338
@NP	the same kind of robust regeneration	52360
@NP	the same kind	52360
@NP	robust regeneration	52377
@NP	this model for lesioned rubrospinal axons	52413
@NP	this model	52413
@NP	lesioned rubrospinal axons	52428
@NP	Rubrospinal neurons	52456
@NP	massive atrophy	52493
@NP	2 weeks	52509
@NP	axotomy	52523
@NP	the expression	52549
@NP	regeneration associated genes	52567
@NP	Kobayashi	52598
@NP	et al. , 1997	52608
@NP	et al.	52608
@NP	1997	52616
@NP	The initial apparent withdrawal	52623
@NP	rubrospinal axons	52658
@NP	the site of lesion/transplant during the first week after surgery	52681
@NP	the site	52681
@NP	lesion/transplant during the first week after surgery	52693
@NP	lesion/transplant	52693
@NP	the first week after surgery	52718
@NP	the first week	52718
@NP	surgery	52739
@NP	most likely limit their access	52753
@NP	most likely limit	52753
@NP	their access	52771
@NP	presumed OEC-derived trophic factors -LRB- Fig. 5 -RRB-	52787
@NP	presumed OEC-derived trophic factors	52787
@NP	Fig. 5	52825
@NP	The subsequent massive invasion of Schwann cells	52834
@NP	The subsequent massive invasion	52834
@NP	Schwann cells	52869
@NP	the local availability of trophic factors	52905
@NP	the local availability	52905
@NP	trophic factors	52931
@NP	rubrospinal axons	52960
@NP	the lesion site	53001
@NP	The inability of the rubrospinal axons to cross the distal lesion host interface	53018
@NP	The inability	53018
@NP	the rubrospinal axons to cross the distal lesion host interface	53035
@NP	the distal lesion host interface	53066
@NP	the failure of the parent cell bodies	53121
@NP	the failure	53121
@NP	the parent cell bodies	53136
@NP	a regenerative response for several weeks	53170
@NP	a regenerative response	53170
@NP	several weeks	53198
@NP	injury	53218
@NP	This transient preparedness of rubrospinal neurons to regenerate	53226
@NP	This transient preparedness	53226
@NP	rubrospinal neurons	53257
@NP	brain-derived neurotrophic factor -LRB- BDNF -RRB-	53309
@NP	brain-derived neurotrophic factor	53309
@NP	BDNF	53344
@NP	secreting fibroblasts	53350
@NP	rubrospinal regeneration	53385
@NP	acute -LRB- Liu et al. , 2002 -RRB- but not chronic -LRB- 4 weeks -RRB- lesion	53416
@NP	Liu et al. , 2002	53423
@NP	Liu	53423
@NP	et al.	53427
@NP	2002	53435
@NP	4 weeks	53458
@NP	Jin	53475
@NP	et al. , 2002	53479
@NP	et al.	53479
@NP	2002	53487
@NP	rubrospinal neurons	53505
@NP	peripheral nerve transplants	53549
@NP	these	53583
@NP	4 weeks	53601
@NP	lesion	53615
@NP	Houle	53623
@NP	1991	53630
@NP	this failure	53641
@NP	trophic support	53689
@NP	the cell body -LRB- Kwon et al. , 2002 -RRB-	53717
@NP	the cell body	53717
@NP	Kwon	53732
@NP	et al. , 2002	53737
@NP	et al.	53737
@NP	2002	53745
@NP	LP-OECs	53752
@NP	angiogenesis	53767
@NP	The transplantation of LP-OECs	53780
@NP	The transplantation	53780
@NP	LP-OECs	53803
@NP	tissue loss	53830
@NP	cavity and scar formation	53855
@NP	the lesion site	53884
@NP	extensive angiogenesis	53915
@NP	the lesion site	53941
@NP	means	53970
@NP	secretion	53979
@NP	VEGF synthesized by LP-OECs -LRB- Au and Roskams , 2003 ; Fig. 6 -RRB-	53992
@NP	VEGF	53992
@NP	LP-OECs -LRB- Au and Roskams , 2003 ; Fig. 6 -RRB-	54012
@NP	LP-OECs	54012
@NP	Au and Roskams	54021
@NP	Au	54021
@NP	Roskams	54028
@NP	2003 ; Fig. 6	54037
@NP	2003	54037
@NP	Fig. 6	54043
@NP	Angiogenesis and reperfusion	54052
@NP	only essential components	54089
@NP	any damaged tissue	54140
@NP	enhanced behavioral recovery after contusion SCI -LRB- Loy et al. , 2002 -RRB-	54205
@NP	enhanced behavioral recovery	54205
@NP	contusion SCI -LRB- Loy et al. , 2002 -RRB-	54240
@NP	contusion SCI	54240
@NP	Loy	54255
@NP	et al. , 2002	54259
@NP	et al.	54259
@NP	2002	54267
@NP	These newly formed blood vessels	54274
@NP	a laminin-rich basal lamina	54323
@NP	the collagen V isoform p200	54370
@NP	Chernousov	54399
@NP	et al. , 1999 , 2000	54410
@NP	et al.	54410
@NP	1999	54418
@NP	2000	54424
@NP	a secreted glycoprotein induced in Schwann cells during regeneration by axon	54431
@NP	a	54431
@NP	glycoprotein induced in Schwann cells during regeneration by axon	54442
@NP	glycoprotein	54442
@NP	Schwann cells	54466
@NP	regeneration	54487
@NP	axon	54503
@NP	glial contact	54508
@NP	This basal lamina deposition	54523
@NP	the migration path of LP-OECs and/or Schwann cells	54577
@NP	the migration path	54577
@NP	LP-OECs and/or Schwann cells	54599
@NP	LP-OECs	54599
@NP	Schwann cells	54614
@NP	a favorable substrate for neurite extension -LRB- Fig. 6 -RRB-	54648
@NP	a favorable substrate	54648
@NP	neurite extension -LRB- Fig. 6 -RRB-	54674
@NP	neurite extension	54674
@NP	Fig. 6	54693
@NP	Allotransplantation of GFP LP-OECs into strainmatched C57/Bl6 mice	54702
@NP	Allotransplantation	54702
@NP	GFP LP-OECs into strainmatched C57/Bl6 mice	54725
@NP	GFP LP-OECs	54725
@NP	strainmatched C57/Bl6 mice	54742
@NP	LP-OECs	54777
@NP	a similar mechanism	54793
@NP	regeneration	54824
@NP	the host	54851
@NP	LP-OECs	54869
@NP	a more amenable host -LRB- Fig. 7 -RRB-	54900
@NP	a more amenable host	54900
@NP	Fig. 7	54922
@NP	cavitation	54940
@NP	this mouse strain	54969
@NP	the glial scar in the presence of LPOECs	54988
@NP	the glial scar	54988
@NP	the presence of LPOECs	55006
@NP	the presence	55006
@NP	LPOECs	55022
@NP	Schwann cells	55069
@NP	the lesion core	55100
@NP	an environment permissive for regeneration	55138
@NP	an environment permissive	55138
@NP	regeneration	55168
@NP	the core of the lesion	55184
@NP	the core	55184
@NP	the lesion	55196
@NP	control mice even without cavitation	55211
@NP	control mice	55211
@NP	cavitation	55237
@NP	the dense , astrocytic-rich barrier and lack of Schwann cell infiltration	55249
@NP	the dense , astrocytic-rich barrier and lack	55249
@NP	Schwann cell infiltration	55296
@NP	the axons	55348
@NP	the lesion center	55372
@NP	the medium-injected mice	55393
@NP	the treated animals	55427
@NP	considerable axon growth throughout the lesioned area	55451
@NP	considerable axon growth	55451
@NP	the lesioned area	55487
@NP	the encouraging and largely positive regeneration effects reported so far	55523
@NP	the encouraging and largely positive regeneration	55523
@NP	effects	55573
@NP	it	55598
@NP	the sensory axon sprouting we detect into the lesion site	55620
@NP	the sensory axon	55620
@NP	we	55647
@NP	the lesion site	55662
@NP	Fig. 5	55709
@NP	significant hyperalgesia	55729
@NP	inappropriate stimulation	55772
@NP	sensory sprouting in both animal and human experimentation	55801
@NP	sensory	55801
@NP	both animal and human experimentation	55822
@NP	animal	55827
@NP	human experimentation	55838
@NP	this	55861
@NP	future paradigms	55900
@NP	OECs	55923
@NP	agents of transplantation -LRB- Romero et al. , 2000 -RRB-	55931
@NP	agents	55931
@NP	transplantation -LRB- Romero et al. , 2000 -RRB-	55941
@NP	transplantation	55941
@NP	Romero	55958
@NP	et al. , 2000	55965
@NP	et al.	55965
@NP	2000	55973
@NP	conclusion	55983
@NP	we	55995
@NP	the first time	56019
@NP	well-defined and reproducible LP-OECs	56039
@NP	repair of spinal cord lesion	56089
@NP	repair	56089
@NP	spinal cord lesion	56099
@NP	a xenotransplant	56127
@NP	novel mechanistic insight	56157
@NP	they	56193
@NP	this	56210
@NP	host glial cells -LRB- Schwann cells and astrocytes -RRB-	56230
@NP	host glial cells	56230
@NP	Schwann cells and astrocytes	56248
@NP	Schwann cells	56248
@NP	astrocytes	56266
@NP	tissue repair	56291
@NP	OECs	56306
@NP	cavity formation	56319
@NP	scar formation	56344
@NP	angiogenesis	56370
@NP	a permissive glial environment	56395
@NP	the lesion site	56429
@NP	axonal growth/regeneration of multiple axonal populations	56456
@NP	axonal growth/regeneration	56456
@NP	multiple axonal populations	56486
@NP	These data	56515
@NP	LPOECs	56541
@NP	prime candidates for autologous transplantation in SCI	56551
@NP	prime candidates	56551
@NP	autologous transplantation in SCI	56572
@NP	autologous transplantation	56572
@NP	SCI	56602
@NP	this approach	56611
@NP	targeted strategies	56649
@NP	axonal regeneration	56691
@NP	the successful re-targeting of axons most desired in human SCI	56714
@NP	the successful re-targeting	56714
@NP	axons most desired in human SCI	56745
@NP	axons	56745
@NP	human SCI	56767
@VP	Reduce Scar and Cavity Formation	40
@VP	Promote Regeneration after Spinal Cord Injury LEANNE M.	77
@VP	minimizing local damage to create an environment permissive for regeneration	500
@VP	to create an environment permissive for regeneration	524
@VP	create an environment permissive for regeneration	527
@VP	to repair spinal cord injury -LRB- SCI -RRB-	630
@VP	repair spinal cord injury -LRB- SCI -RRB-	633
@VP	are prime candidates for autologous transplantation to bridge this gap	701
@VP	to bridge this gap	753
@VP	bridge this gap	756
@VP	is known currently about their mechanism of action	784
@VP	known currently about their mechanism of action	787
@VP	to be tested for their ability to promote regeneration in established SCI models	966
@VP	be tested for their ability to promote regeneration in established SCI models	969
@VP	tested for their ability to promote regeneration in established SCI models	972
@VP	to promote regeneration in established SCI models	997
@VP	promote regeneration in established SCI models	1000
@VP	demonstrate limited migration	1195
@VP	to develop a new transitional zone at the lesion border	1259
@VP	develop a new transitional zone at the lesion border	1262
@VP	stimulate angiogenesis to provide a biological scaffold for repair	1427
@VP	to provide a biological scaffold for repair	1450
@VP	provide a biological scaffold for repair	1453
@VP	created by transplanted and host glia within the spinal cord	1518
@VP	inhibits cavity and scar formation	1579
@VP	sprouting of multiple sensory and motor axons into and through the lesion site	1637
@VP	did not	1881
@VP	to create an environment to ameliorate local damage	1982
@VP	create an environment to ameliorate local damage	1985
@VP	to ameliorate local damage	2007
@VP	ameliorate local damage	2010
@VP	promote a regenerative response in multiple axonal populations	2053
@VP	still results in permanent neurologic deficits	2246
@VP	confined within the central nervous system	2461
@VP	results in successful axonal regeneration	2699
@VP	does occur	2892
@VP	occur	2897
@VP	are highly plastic	3620
@VP	support axonal regeneration	4018
@VP	targeting in the CNS portion of the olfactory system	4050
@VP	have been isolated , transplanted ,	4155
@VP	been isolated , transplanted ,	4160
@VP	isolated , transplanted ,	4165
@VP	reviewed by Bartolomei and Greer , 2000 ; Bunge , 2002	4276
@VP	preparing OECs	4741
@VP	may change with time in culture or frequency of passage	4817
@VP	change with time in culture or frequency of passage	4821
@VP	reviewed in Franklin , 2002	4912
@VP	marking the cells stably enough	5088
@VP	to follow them in the complex environment of a spinal cord	5120
@VP	follow them in the complex environment of a spinal cord	5123
@VP	to optimize their use in a transplantation approach	5272
@VP	optimize their use in a transplantation approach	5275
@VP	has been used in several cases	5546
@VP	been used in several cases	5550
@VP	used in several cases	5555
@VP	frequently leak	5593
@VP	have thus far been tested in transplantation paradigms	5812
@VP	been tested in transplantation paradigms	5826
@VP	tested in transplantation paradigms	5831
@VP	has largely been restricted to acute SCI models	5882
@VP	been restricted to acute SCI models	5894
@VP	restricted to acute SCI models	5899
@VP	remain untested in animal models of SCI	6057
@VP	containing a highly heterogeneous mixture of different cells	6161
@VP	-RRB-	6521
@VP	purified	6544
@VP	characterized LP-OECs	6554
@VP	combining GFP fluorescence with species-specific antibodies	6707
@VP	to remodel the spinal cord lesion environment	7010
@VP	remodel the spinal cord lesion environment	7013
@VP	can sprout and mount a regeneration response	7127
@VP	sprout and mount a regeneration response	7131
@VP	expressing eGFP -LRB- GFP-U-NAGY ; generated by Andreas Nagy , U.	7319
@VP	generated	7348
@VP	digested with 1.2 mg/ml collagenase D	7617
@VP	described to remove contaminating fibroblasts	8101
@VP	to remove contaminating fibroblasts	8111
@VP	remove contaminating fibroblasts	8114
@VP	grew to confluency -LRB- 2 -- 4 further DIV -RRB- before transplantation	8253
@VP	to be harvested freshly for transplantation into each animal	8484
@VP	be harvested freshly for transplantation into each animal	8487
@VP	harvested freshly for transplantation into each animal	8490
@VP	ranged from 11 to 14 DIV	8596
@VP	using freshly prepared LPOECs	8651
@VP	indicated maintenance of phenotype after cryopreservation of cells	8681
@VP	to determine the purity of OECs used for grafting	9072
@VP	determine the purity of OECs used for grafting	9075
@VP	used for grafting	9104
@VP	grafting	9113
@VP	used to test culture purity	9142
@VP	to test culture purity	9147
@VP	test culture purity	9150
@VP	raised in goat and conjugated to Alexa 594 for 1 hour at room temperature	9477
@VP	raised in goat	9477
@VP	conjugated to Alexa 594 for 1 hour at room temperature	9496
@VP	dipped in Hoechst	9552
@VP	commencing 2 days before injury and OEC transplantation	9951
@VP	were maintained throughout survival	10011
@VP	maintained throughout survival	10016
@VP	approved by our institution 's animal care committee	10163
@VP	expose the left half of the fourth cervical spinal cord segment -LRB- C4 -RRB-	10339
@VP	was cut with microscissors	10422
@VP	cut with microscissors	10426
@VP	were closed and held for 18	10616
@VP	closed and held for 18	10621
@VP	to crush the dorsolateral funiculus , including the rubrospinal tract	10655
@VP	crush the dorsolateral funiculus , including the rubrospinal tract	10658
@VP	designated as treated or control by an investigator other than the surgeon	10778
@VP	treated or control by an investigator other than the surgeon	10792
@VP	treated	10792
@VP	control by an investigator other than the surgeon	10803
@VP	were harvested in 0.25 % trypsin and 1 % ethylenediaminetetraacetic acid	10915
@VP	harvested in 0.25 % trypsin and 1 % ethylenediaminetetraacetic acid	10920
@VP	buffered saline -LRB- PBS -RRB- , and resuspended in Dulbecco 's	11015
@VP	buffered saline -LRB- PBS -RRB-	11015
@VP	resuspended in Dulbecco 's	11042
@VP	modified Eagles medium -LRB- DMEM -RRB- at 50,000 -- 100,000 OECs/µl	11068
@VP	divided over three injection sites	11241
@VP	glued to a Hamilton syringe	11388
@VP	was introduced at a rate of 100 nl/min	11433
@VP	introduced at a rate of 100 nl/min	11437
@VP	remained in place for 5 minutes after each injection	11489
@VP	received identical volumes of DMEM injected at the same rate and sites	11559
@VP	injected at the same rate and sites	11594
@VP	was slowly withdrawn	11670
@VP	slowly withdrawn	11674
@VP	were closed with interrupted sutures	11715
@VP	closed with interrupted sutures	11720
@VP	were anesthetized	11983
@VP	placed in a Kopf stereotaxic frame	12002
@VP	was stereotaxically injected into the red nucleus at a rate of 80 nl/min	12163
@VP	injected into the red nucleus at a rate of 80 nl/min	12183
@VP	Coordinates used	12237
@VP	used	12249
@VP	were 5.9 mm caudal to bregma , 0.7 mm lateral to midline , and 7 mm deep	12254
@VP	varied with animal size from 0.5 -- 0.8 µl	12349
@VP	remained in place for 5 minutes after injection	12406
@VP	killed with an overdose of chloral hydrate -LRB- 100 mg/kg , i.p. -RRB-	12524
@VP	perfused transcardially with PBS	12589
@VP	followed by phosphate buffered , 4 % paraformaldehyde -LRB- pH 7.4 -RRB-	12622
@VP	buffered	12644
@VP	dissected	12715
@VP	frozen in isopentane over dry ice	12857
@VP	cut into 20-micron longitudinal sections in the horizontal plane on a cryostat	12929
@VP	stored at -80 °C	13012
@VP	thawed on a slide warmer for 5 minutes	13050
@VP	rehydrated in PBS , permeabilized for 1 hour in 0.1 % Triton-X 100 ,	13090
@VP	incubated with 10 % goat serum for 20 minutes to prevent nonspecific binding	13160
@VP	to prevent nonspecific binding	13205
@VP	prevent nonspecific binding	13208
@VP	were applied overnight at 4 °C	13961
@VP	applied overnight at 4 °C	13966
@VP	raised in goat or donkey	14030
@VP	conjugated to Alexa 594 , Alexa 488 , Alexa 350 , Cy3 , or aminomethylcoumarin	14059
@VP	were applied for 1 hour at room temperature	14141
@VP	applied for 1 hour at room temperature	14146
@VP	applied for 1 hour at room temperature	14268
@VP	using Northern Eclipse and SigmaScan Pro -LRB- SPSS Inc. , Chicago , IL -RRB-	14692
@VP	was used to compare treatment groups	15107
@VP	used to compare treatment groups	15111
@VP	to compare treatment groups	15116
@VP	compare treatment groups	15119
@VP	drawn perpendicular to the dorsal columns , through the lesion epicenter	15280
@VP	were grouped together -LRB- not summed -RRB- for each time point	15437
@VP	grouped together -LRB- not summed -RRB- for each time point	15442
@VP	were excluded	15516
@VP	excluded	15521
@VP	were taken from 100 images of three-to-five longitudinal sections per animal	15544
@VP	taken from 100 images of three-to-five longitudinal sections per animal	15549
@VP	Fig. 1	15632
@VP	declined steadily from 2 to 60 days	16179
@VP	bar = 400 µm in a -LRB- applies to a -- h -RRB-	16870
@VP	applies to a -- h	16889
@VP	sprout into and across the olfactory ensheathing cell -LRB- OEC -RRB-	20123
@VP	applies to a , b , d , f , h , j	21256
@VP	is marked on each image with an arrowhead	22667
@VP	marked on each image with an arrowhead	22670
@VP	marks the center of the lesion site in each panel	22722
@VP	applies	22799
@VP	µm in f	22839
@VP	bar = 200 µm in a -LRB- applies to a -- h -RRB-	25944
@VP	applies to a -- h	25963
@VP	could be used for a series of cross-comparative transplantation studies	26031
@VP	be used for a series of cross-comparative transplantation studies	26037
@VP	used for a series of cross-comparative transplantation studies	26040
@VP	expressing eGFP driven by a CMV : betta-actin promoter	26238
@VP	driven by a CMV	26254
@VP	subsequently used in transplantation	26492
@VP	tested 24 hours before transplantation	26534
@VP	found to be 98 -- 100 % pure OECs by both antigenic and morphologic analysis	26591
@VP	to be 98 -- 100 % pure OECs by both antigenic and morphologic analysis	26597
@VP	be 98 -- 100 % pure OECs by both antigenic and morphologic analysis	26600
@VP	were detected between LP-OECs cultured fresh	26997
@VP	detected between LP-OECs cultured fresh	27002
@VP	cultured fresh	27027
@VP	frozen after 9 DIV	27124
@VP	passaged four times -LRB- data not shown ; Au and Roskams , 2003 -RRB-	27147
@VP	not shown	27173
@VP	integrate and reduce cavity formation	27215
@VP	reflects the most common features of spinal cord pathology reported in human SCI	27456
@VP	reported in human SCI	27515
@VP	being tested within our laboratories	27650
@VP	tested within our laboratories	27656
@VP	transplanting OB-OECs into rat SCI	27726
@VP	resembled that seen in rats with lesion but no medium -LRB- W.	28425
@VP	that seen in rats with lesion but no medium -LRB- W.	28435
@VP	reaching maximal diameters of 0.5 to 1 mm -LRB- Fig. 1e , g -RRB-	28566
@VP	received OEC injections	28714
@VP	was 0.735 ± 0.293 mm2	28986
@VP	received OECs , 0.01 ± 0.004 mm2	29029
@VP	declined from 2 to 28 days	29187
@VP	to assess survival and migration of the injected OECs	29255
@VP	assess survival and migration of the injected OECs	29258
@VP	be detected in the center of the lesion site 2 days after transplantation	29342
@VP	detected in the center of the lesion site 2 days after transplantation	29345
@VP	widened	29581
@VP	extended , from the lesion center into the host tissue -LRB- Fig. 1d -RRB-	29598
@VP	detected more than 400 microns away from lesion epicenter -LRB- Fig 1f , i -RRB-	29710
@VP	surviving 28 days	29845
@VP	surviving 60 days	29896
@VP	to control for potential down-regulation of GFP	29982
@VP	control for potential down-regulation of GFP	29985
@VP	confirmed those for endogenous GFP fluorescence , -LRB- data not shown -RRB-	30049
@VP	not shown	30104
@VP	invaded the lesion site	30232
@VP	could be seen along the degenerating dorsolateral funiculus	30260
@VP	be seen along the degenerating dorsolateral funiculus	30266
@VP	seen along the degenerating dorsolateral funiculus	30269
@VP	eGFPexpressing OECs compared with the persistence of p75	30447
@VP	reported by others	30534
@VP	using a polyclonal antibody recognizing both rat and mouse p75	30721
@VP	recognizing both rat and mouse p75	30749
@VP	reported by others	30916
@VP	accompanied by NF200-positive axons	30937
@VP	not shown	31108
@VP	persisting at the lesion site at 28 days after lesion	31279
@VP	reviewed in Fraher , 1999	31558
@VP	recognizing a rat-specific form of p75	31771
@VP	resembling migrating Schwann cells	31976
@VP	migrating Schwann cells	31987
@VP	intermingling with	32091
@VP	surrounded by transplanted GFPpositive OECs -LRB- Fig. 2a -RRB-	32114
@VP	increasing times after lesion	32172
@VP	infiltrating Schwann cells	32203
@VP	migrated out further from the lesion center	32230
@VP	interdigitating with other glial cells -LRB- Fig. 2b , d , e -RRB-	32530
@VP	remaining transplanted OECs	32614
@VP	were confined to the center of the lesion site	32642
@VP	confined to the center of the lesion site	32647
@VP	infiltrating Schwann cells	32691
@VP	pioneered by transplanted LP-OECs -LRB- Fig. 2f , g -RRB-	32809
@VP	to consist of a laminin-rich substrate	32880
@VP	consist of a laminin-rich substrate	32883
@VP	expressing S100 that were additionally eGFP-negative and GFAP-negative	33251
@VP	were additionally eGFP-negative and GFAP-negative	33272
@VP	not shown	33328
@VP	might also alter the formation of a gliotic scar at the lesion boundary	33513
@VP	alter the formation of a gliotic scar at the lesion boundary	33524
@VP	can also mitigate the reactive astrocytic response in vitro	33839
@VP	mitigate the reactive astrocytic response in vitro	33848
@VP	to reduce gliotic scarring in SCI -LRB- Lakatos et al. , 2000 -RRB-	33954
@VP	reduce gliotic scarring in SCI -LRB- Lakatos et al. , 2000 -RRB-	33957
@VP	to examine scar formation at the lesion site -LRB- Fig. 3 -RRB-	34098
@VP	examine scar formation at the lesion site -LRB- Fig. 3 -RRB-	34101
@VP	reviewed in Fawcett and Asher , 1999 ; Steward et al. , 1999	34254
@VP	received OEC transplants	34511
@VP	extending toward the lesion center -LRB- Fig. 3c , d -RRB-	34704
@VP	emanating from the lesion center	34853
@VP	seen in Fig. 2	34887
@VP	seen in control animals	34959
@VP	compare Figs. 2 and 3	34984
@VP	was diffuse and oriented	35067
@VP	inhibiting gliosis and CSPG deposition	35215
@VP	extending from the edge of the lesion	35400
@VP	prevented the formation of a characteristic dense scar barrier	35442
@VP	forming an astrocytic barrier to regeneration	35527
@VP	appeared permissive to axonal growth	35613
@VP	entering the lesion site after traveling along and through the reorganized	35698
@VP	traveling along	35729
@VP	aligned GFAP-positive astrocytes -LRB- Fig. 3e , f -RRB-	35774
@VP	was not determined	35855
@VP	determined	35863
@VP	appeared to be crossing the host / lesion interface -LRB- Fig. 3e -RRB-	35880
@VP	to be crossing the host / lesion interface -LRB- Fig. 3e -RRB-	35889
@VP	be crossing the host / lesion interface -LRB- Fig. 3e -RRB-	35892
@VP	crossing the host / lesion interface -LRB- Fig. 3e -RRB-	35895
@VP	may have allowed axonal regeneration	36107
@VP	have allowed axonal regeneration	36111
@VP	allowed axonal regeneration	36116
@VP	sprouting through the lesion site	36147
@VP	expressing a variety of neuronal markers by immunostaining for axonal antigens	36218
@VP	approached or grew along the wall of the cavity	36447
@VP	could no longer be detected at 60 days	36599
@VP	be detected at 60 days	36615
@VP	detected at 60 days	36618
@VP	had received OEC injections	36653
@VP	received OEC injections	36657
@VP	showed robust growth of axons into the lesion site -LRB- Fig. 4b -- k -RRB-	36681
@VP	occupying the lesion site	36751
@VP	both large and small in diameter	36782
@VP	stained for NF200 and IIIT -LRB- Fig. 4b -- e -RRB-	36819
@VP	indicated by expression of 5HT , TH , and CGRP -LRB- Fig. 4f -- k -RRB-	36938
@VP	to relate to their site of origin	37050
@VP	relate to their site of origin	37053
@VP	running laterally across the lesion site	37188
@VP	expressing 5HT and TH	37391
@VP	displayed a typical beaded axonal staining pattern	37413
@VP	grew robustly into the glia-rich lesion site	37468
@VP	examined	37552
@VP	to cross the caudal lesion -- host interface -LRB- Fig. 4g , i , arrows -RRB-	37583
@VP	cross the caudal lesion -- host interface -LRB- Fig. 4g , i , arrows -RRB-	37586
@VP	extending several millimeters distally	37656
@VP	expressing CGRP	37739
@VP	were also clearly visible in the OEC-treated lesion site -LRB- Fig. 4k -RRB-	37755
@VP	is stimulated	37852
@VP	stimulated	37855
@VP	was clear that transplanted mouse LP-OECs were able to minimize the appar	37963
@VP	were able to minimize the appar	38005
@VP	to minimize the appar	38015
@VP	minimize the appar	38018
@VP	decreasing cavity and scar barrier formation	38078
@VP	killing to trace regenerating tracts -LRB- Fig. 5 -RRB-	38514
@VP	to trace regenerating tracts -LRB- Fig. 5 -RRB-	38522
@VP	trace regenerating tracts -LRB- Fig. 5 -RRB-	38525
@VP	regenerating tracts -LRB- Fig. 5 -RRB-	38531
@VP	seen rostral to the border of the cavity 7 days after injury -LRB- Fig. 5a -RRB-	38609
@VP	displayed morphologic characteristics of end-bulbs -LRB- Fig. 5b -RRB-	38788
@VP	received LP-OEC transplants	38863
@VP	were detected close to the rostral edge of the injury site	38904
@VP	detected close to the rostral edge of the injury site	38909
@VP	sprouted into the OEC transplant at 7 days -LRB- Fig. 5c -RRB-	38973
@VP	ended 300 m rostral to the lesion center in control animals	39061
@VP	stopped short 500 µm rostral to the lesion center with OEC transplantation	39126
@VP	were still in proximity to the rostral edge of the cavity	39274
@VP	were never seen to grow around the lesion -LRB- Fig. 5d , g -RRB-	39336
@VP	seen to grow around the lesion -LRB- Fig. 5d , g -RRB-	39347
@VP	to grow around the lesion -LRB- Fig. 5d , g -RRB-	39352
@VP	grow around the lesion -LRB- Fig. 5d , g -RRB-	39355
@VP	ended several hundred microns proximal to lesion -LRB- e.g. , Fig. 5e -RRB-	39450
@VP	could no longer be detected	39760
@VP	be detected	39776
@VP	detected	39779
@VP	i	39797
@VP	formed by migrating glial cells and sprouting axons at the lesion site	40073
@VP	migrating glial cells and sprouting axons at the lesion site	40083
@VP	migrating glial cells	40083
@VP	sprouting axons at the lesion site	40109
@VP	might represent sites of local angiogenesis	40144
@VP	represent sites of local angiogenesis	40150
@VP	recognizing RECA-1 -LRB- Fig. 6 -RRB-	40304
@VP	surrounded the lesion site	40405
@VP	were in direct contact with both GFP-positive LP-OECs -LRB- Fig. 6a , b -RRB-	40541
@VP	were also surrounded by rat p75-positive/p200	40611
@VP	also surrounded by rat p75-positive/p200	40616
@VP	extending into the lesion center	40700
@VP	making direct contacts with transplanted LP-OECs -LRB- Fig. 6e , f -RRB-	40804
@VP	differ significantly from most other reports using vital dye labeling	41158
@VP	using vital dye labeling	41203
@VP	dye labeling	41215
@VP	could be due to xenotransplantation	41228
@VP	be due to xenotransplantation	41234
@VP	used to generate the GFP-positive LPOECs	41601
@VP	to generate the GFP-positive LPOECs	41606
@VP	generate the GFP-positive LPOECs	41609
@VP	used for the rats -LRB- Fig. 7 -RRB-	41701
@VP	seen in the rat	41757
@VP	was observed	41773
@VP	observed	41777
@VP	examined -LRB- seven of seven ; Fig. 7b -RRB-	41938
@VP	is known to be minimal -LRB- Steward et al. , 1999 -RRB-	42175
@VP	known to be minimal -LRB- Steward et al. , 1999 -RRB-	42178
@VP	to be minimal -LRB- Steward et al. , 1999 -RRB-	42184
@VP	be minimal -LRB- Steward et al. , 1999 -RRB-	42187
@VP	were not assessed	42255
@VP	assessed	42264
@VP	surrounding the lesion	42320
@VP	had received GFP-positive LPOEC transplants	42388
@VP	received GFP-positive LPOEC transplants	42392
@VP	contained no indication of dense scar formation	42455
@VP	was also enhanced after transplantation of LP-OECs -LRB- Fig. 7c -- f -RRB-	42566
@VP	enhanced after transplantation of LP-OECs -LRB- Fig. 7c -- f -RRB-	42575
@VP	ventured to the scar boundary	42790
@VP	cross the lesion center in the control group -LRB- Fig. 7e -RRB- DISCUSSION Here	42839
@VP	purified	42912
@VP	transplanted into acute spinal cord injury sites	42966
@VP	create a unique environment to support regeneration	43089
@VP	to support regeneration	43117
@VP	support regeneration	43120
@VP	will even do this in a xenotransplantation paradigm	43305
@VP	do this in a xenotransplantation paradigm	43315
@VP	prevented cavity formation	43459
@VP	attenuated glial scar formation	43487
@VP	facilitated the invasion of host Schwann cells	43520
@VP	stimulated extensive sprouting	43621
@VP	sprouting	43642
@VP	to consistently and reliably assess the fate of the transplanted LP-OECs	44248
@VP	consistently and reliably assess the fate of the transplanted LP-OECs	44251
@VP	delineated microscopically -LRB- Fig. 1 -RRB-	44451
@VP	down radially aligned channels into the host cord surrounding the lesion site	44517
@VP	surrounding the lesion site	44567
@VP	was short-lived	44652
@VP	declined from 28 to 60 days	44687
@VP	could not be detected in the rat spinal cord by 60 days after transplantation	44719
@VP	be detected in the rat spinal cord by 60 days after transplantation	44729
@VP	detected in the rat spinal cord by 60 days after transplantation	44732
@VP	Given that mouse LP-OECs did survive longer in a mouse-lesion site	44798
@VP	did survive longer in a mouse-lesion site	44823
@VP	survive longer in a mouse-lesion site	44827
@VP	xenotransplanted cells , despite treatment with cyclosporin A.	44976
@VP	might not adapt as well as OB-OECs to migrating through a CNS environment	45061
@VP	adapt as well as OB-OECs to migrating through a CNS environment	45071
@VP	migrating through a CNS environment	45099
@VP	virally labeled rat OB-OECs transplanted into a similar rat lesion	45167
@VP	transplanted into a similar rat lesion	45195
@VP	have reported more extensive migration and survival	45387
@VP	reported more extensive migration and survival	45392
@VP	to identify transplanted OECs in the spinal cord in vivo	45958
@VP	identify transplanted OECs in the spinal cord in vivo	45961
@VP	to counteract normal barriers to regeneration	46464
@VP	counteract normal barriers to regeneration	46467
@VP	was the lack of cavity at the lesion site -LRB- Figs. 1 , 2 -RRB-	46567
@VP	seen in control rats	46647
@VP	require a growth substrate for elongation	46734
@VP	appear similar to those in humans , preventing their formation	46802
@VP	preventing their formation	46837
@VP	reviewed in Schwab , 2002	46932
@VP	invade into the core of the lesion	47044
@VP	migrate to the marginal zone of the cell transplant -LRB- Fig. 2 -RRB-	47088
@VP	became confined to the lesion core	47158
@VP	confined to the lesion core	47165
@VP	outlined by the early migrating OECs	47293
@VP	attempt to migrate into lesioned spinal cord -LRB- Brook et al. , 1998 -RRB-	47364
@VP	to migrate into lesioned spinal cord -LRB- Brook et al. , 1998 -RRB-	47372
@VP	migrate into lesioned spinal cord -LRB- Brook et al. , 1998 -RRB-	47375
@VP	is usually stalled by the hostile environment of the lesion site	47446
@VP	stalled by the hostile environment of the lesion site	47457
@VP	do not usually penetrate further	47520
@VP	penetrate further	47535
@VP	showed very limited Schwann cell invasion	47587
@VP	facilitates migration and integration of infiltrating Schwann cells	47701
@VP	infiltrating Schwann cells	47742
@VP	are the cellular substrate for successful regeneration in the PNS	47784
@VP	aligned in minichannels	47860
@VP	reviewed in Kocsis et al. , 2002	48299
@VP	regenerating axons from the Schwann cells	48374
@VP	grafts into the host spinal cord has been limited	48416
@VP	has been limited	48449
@VP	been limited	48453
@VP	limited	48458
@VP	can access the lesion site	48843
@VP	access the lesion site	48847
@VP	is conducive to both axonal growth and modification of the graft	48926
@VP	normally formed around the cavity of a spinal cord lesion	49034
@VP	reviewed in Fawcett , 2002	49139
@VP	forming the tight pericavity boundary characteristic of glial scar formation	49184
@VP	formed by invading LP-OECs -LRB- Fig. 3 -RRB-	49390
@VP	invading LP-OECs -LRB- Fig. 3 -RRB-	49400
@VP	interdigitate with invading Schwann cells	49528
@VP	invading Schwann cells	49547
@VP	allow descending spinal tracts to cross the distal lesion -- host interface	49574
@VP	descending spinal tracts to cross the distal lesion -- host interface	49580
@VP	to cross the distal lesion -- host interface	49605
@VP	cross the distal lesion -- host interface	49608
@VP	did not appear to be markedly changed	50022
@VP	appear to be markedly changed	50030
@VP	to be markedly changed	50037
@VP	be markedly changed	50040
@VP	closely apposed to astrocytes	50156
@VP	dispersed CSPG deposition	50665
@VP	secrete permissive matrix	50769
@VP	change the local environment from inhibitory to supportive of regeneration	50812
@VP	may have	51064
@VP	have	51068
@VP	promoting invasion of host Schwann cells	51126
@VP	lay the groundwork for creating a permissive PNS environment at the site of SCI	51202
@VP	creating a permissive PNS environment at the site of SCI	51225
@VP	significant barriers to regeneration	51354
@VP	allow in-growth of multiple brainstem spinal tracts	51426
@VP	created by LP-OEC transplantation	51581
@VP	did promote in-growth	51615
@VP	promote in-growth	51619
@VP	observed in this study	51780
@VP	observed in an open field locomotion test -LRB- Lu et al. , 2002 -RRB-	52284
@VP	was not seen in this model for lesioned rubrospinal axons	52397
@VP	seen in this model for lesioned rubrospinal axons	52405
@VP	undergo massive atrophy 2 weeks after axotomy	52485
@VP	encouraging rubrospinal axons to finally sprout into the lesion site	52948
@VP	to finally sprout into the lesion site	52978
@VP	finally sprout into the lesion site	52981
@VP	to cross the distal lesion host interface	53057
@VP	cross the distal lesion host interface	53060
@VP	to sustain a regenerative response for several weeks after injury	53159
@VP	sustain a regenerative response for several weeks after injury	53162
@VP	to regenerate	53277
@VP	regenerate	53280
@VP	is also seen when brain-derived neurotrophic factor -LRB- BDNF -RRB-	53291
@VP	seen when brain-derived neurotrophic factor -LRB- BDNF -RRB-	53299
@VP	are offered 4 weeks after lesion -LRB- Houle , 1991 -RRB-	53589
@VP	offered 4 weeks after lesion -LRB- Houle , 1991 -RRB-	53593
@VP	is given at the cell body -LRB- Kwon et al. , 2002 -RRB-	53705
@VP	given at the cell body -LRB- Kwon et al. , 2002 -RRB-	53708
@VP	minimizes tissue loss and prevents cavity and scar formation at the lesion site	53820
@VP	minimizes tissue loss	53820
@VP	prevents cavity and scar formation at the lesion site	53846
@VP	stimulates extensive angiogenesis at the lesion site	53904
@VP	synthesized by LP-OECs -LRB- Au and Roskams , 2003 ; Fig. 6 -RRB-	53997
@VP	repair any damaged tissue	54133
@VP	secreted glycoprotein induced in Schwann cells during regeneration by axon	54433
@VP	induced in Schwann cells during regeneration by axon	54455
@VP	correlates strongly with the migration path of LP-OECs and/or Schwann cells	54552
@VP	appears to form a favorable substrate for neurite extension -LRB- Fig. 6 -RRB-	54632
@VP	to form a favorable substrate for neurite extension -LRB- Fig. 6 -RRB-	54640
@VP	form a favorable substrate for neurite extension -LRB- Fig. 6 -RRB-	54643
@VP	may use a similar mechanism to promote regeneration regardless of the host	54785
@VP	use a similar mechanism to promote regeneration regardless of the host	54789
@VP	to promote regeneration regardless of the host	54813
@VP	promote regeneration regardless of the host	54816
@VP	will persist better in a more amenable host -LRB- Fig. 7 -RRB-	54877
@VP	persist better in a more amenable host -LRB- Fig. 7 -RRB-	54882
@VP	does not occur in this mouse strain	54951
@VP	occur in this mouse strain	54960
@VP	was once again diffuse and reorganized	55029
@VP	reorganized	55056
@VP	infiltrated into the lesion core	55083
@VP	to provide an environment permissive for regeneration in the core of the lesion	55127
@VP	provide an environment permissive for regeneration in the core of the lesion	55130
@VP	crossing the lesion center in the medium-injected mice	55363
@VP	had considerable axon growth throughout the lesioned area	55447
@VP	reported so far	55581
@VP	sprouting we detect into the lesion site	55637
@VP	detect into the lesion site	55650
@VP	may not ultimately be desired -LRB- Fig. 5 -RRB-	55678
@VP	be desired -LRB- Fig. 5 -RRB-	55697
@VP	desired -LRB- Fig. 5 -RRB-	55700
@VP	sprouting in both animal and human experimentation	55809
@VP	using OECs as agents of transplantation -LRB- Romero et al. , 2000 -RRB-	55917
@VP	may achieve this	56198
@VP	achieve this	56202
@VP	to assist in tissue repair	56278
@VP	assist in tissue repair	56281
@VP	modify scar formation	56337
@VP	stimulate angiogenesis	56360
@VP	to promote axonal growth/regeneration of multiple axonal populations	56445
@VP	promote axonal growth/regeneration of multiple axonal populations	56448
@VP	establish LPOECs as prime candidates for autologous transplantation in SCI	56531
@VP	most desired in human SCI	56751
@VP	is to be achieved	56777
@VP	to be achieved	56780
@VP	be achieved	56783
@VP	achieved	56786
